KR102359655B1 - Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same - Google Patents

Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same Download PDF

Info

Publication number
KR102359655B1
KR102359655B1 KR1020200088369A KR20200088369A KR102359655B1 KR 102359655 B1 KR102359655 B1 KR 102359655B1 KR 1020200088369 A KR1020200088369 A KR 1020200088369A KR 20200088369 A KR20200088369 A KR 20200088369A KR 102359655 B1 KR102359655 B1 KR 102359655B1
Authority
KR
South Korea
Prior art keywords
bacteriophage
opt
listeria
present
bacteria
Prior art date
Application number
KR1020200088369A
Other languages
Korean (ko)
Other versions
KR20220009766A (en
Inventor
연영은
김영주
김현일
한성준
Original Assignee
주식회사 옵티팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 옵티팜 filed Critical 주식회사 옵티팜
Priority to KR1020200088369A priority Critical patent/KR102359655B1/en
Publication of KR20220009766A publication Critical patent/KR20220009766A/en
Application granted granted Critical
Publication of KR102359655B1 publication Critical patent/KR102359655B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40Viruses, e.g. bacteriophages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00031Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

본 발명은 신규한 리스테리아균 특이 박테리오파지 OPT-LM1에 관한 것으로서, 더욱 상세하게는 상기 리스테리아균 특이 박테리오파지 OPT-LM1을 포함하는 항균 조성물에 관한 것이다. 본 발명에 따른 박테리오파지 OPT-LM1은 리스테리아균에 대한 특이성이 매우 높고, 리스테리아균에 감염하여 리스테리아균 내에서 증식함으로써 용균 활성이 우수하며, 물리화학적 자극에 강하다는 장점을 가지고 있다. 또한 본 발명의 박테리오파지 OPT-LM1은 사람, 동물, 식물 등 세균 외의 다른 숙주에는 감염되지 않으므로, 항생제의 오남용으로 인한 항생제 내성균의 문제점, 식품 내의 항생제 잔류 문제, 광범위한 숙주범위의 문제점을 해결할 수 있는바, 항생용 조성물, 사료 첨가용 조성물, 사료, 소독제 또는 세척제 분야에서 다양하게 활용될 수 있다. The present invention relates to a novel Listeria-specific bacteriophage OPT-LM1, and more particularly, to an antibacterial composition comprising the Listeria-specific bacteriophage OPT-LM1. Bacteriophage OPT-LM1 according to the present invention has a very high specificity to Listeria, has excellent lytic activity by being infected with Listeria and proliferated in Listeria, and has the advantage of being strong in physicochemical stimuli. In addition, the bacteriophage OPT-LM1 of the present invention does not infect other hosts other than bacteria, such as humans, animals, and plants, so it is possible to solve the problems of antibiotic-resistant bacteria due to the misuse of antibiotics, the problem of antibiotic residue in food, and the problem of a wide host range. , can be used in various ways in the field of antibiotic composition, feed additive composition, feed, disinfectant or cleaning agent.

Figure 112020074301012-pat00004
Figure 112020074301012-pat00004

Description

신규한 리스테리아균 특이 박테리오파지 OPT-LM1 및 이를 포함하는 항균 조성물{Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same}Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same

본 발명은 신규한 리스테리아균 특이 박테리오파지 OPT-LM1에 관한 것으로서, 더욱 상세하게는 상기 리스테리아균 특이 박테리오파지 OPT-LM1을 포함하는 항균 조성물에 관한 것이다. The present invention relates to a novel Listeria-specific bacteriophage OPT-LM1, and more particularly, to an antibacterial composition comprising the Listeria-specific bacteriophage OPT-LM1.

리스테리아균은 동물의 장내, 자연환경 등에 분포되어 있으며 육가공품, 유제품, 채소 및 즉석식품 등 다양한 식품에서 검출되어 사회적으로 문제가 되고 있다. 최적성장 온도는 37℃이나 10℃이하의 온도에서도 증식이 가능하며 냉장온도에서도 증식이 가능하기 때문에 냉장, 저장 식품을 통해 식중독을 발생시키며, 콜드체인 시스템이 발달되어 있는 선진국에서 식중독이 많이 발생하여 선진국형 식중독균으로 알려져 있다. 리스테리아에는 다수의 균종이 있으며 이 중 리스테리아 모노사이토제네스(Listeria monocytogenes)와 리스테리아 이바노비(Listeria ivanovii)의 두 균주가 인체에 병원성을 나타낸다. 그 중 리스테리아 모노사이토제네스는 통성혐기성의 그람양성 간균으로 농축수산 식품 등 다양한 경로를 통해 식중독을 일으키는 원인균이다. 따라서, 주로 리스테리아 모노사이토제네스에 의한 감염 사례가 많으며, 리스테리아 감염증은 감염 빈도는 낮으나 미국에서는 20~40%의 높은 치사율을 보이고 있다. 건강한 사람에게는 설사, 발열, 두통, 근육통 및 위장관염을 일으키며 잠복기가 짧은 편이다. 면역 기능이 저하된 환자, 임산부, 노인 및 유아에서는 패혈증, 뇌수막염 등을 일으킬 수 있다. 또한 임산부는 다른 건강한 성인보다 리스테리아 감염증에 걸릴 확률이 약 20배 더 높으며 유산이나 사산의 원인이 된다. 또한, 리스테릭 뇌막염(listeric meningitis)의 경우 치사율은 70% 정도이며, 패혈증의 치사율은 50%, 임신 중 또는 신생아의 경우 80% 정도이다. 항생제로 치료가 가능하나 리스테리아균이 세포 내에 기생하기 때문에 항생제가 세포 내로 침투해야 효능이 나타나 치료가 어려운 점이 있으며 고염농도 및 저온상태의 환경에서도 적응하여 균의 오염 예방이 어려우므로 식품 제조 단계에서 균의 오염방지 및 제거가 최선의 방법이다.Listeria bacteria are distributed in the intestines of animals and in the natural environment, and are detected in various foods such as meat products, dairy products, vegetables and instant foods, which is a social problem. The optimum growth temperature is 37℃ or 10℃ or lower, and since it can grow even at refrigerated temperatures, food poisoning occurs through refrigerated and stored foods. It is known as an advanced food poisoning bacteria. Listeria has a number of strains, of which Listeria monocytogenes ( Listeria monocytogenes ) and Listeria ivanovii ( Listeria ivanovii ) Two strains are pathogenic to the human body. Among them, Listeria monocytogenes is a facultative anaerobic Gram-positive bacillus that causes food poisoning through various routes such as concentrated seafood. Therefore, there are many cases of infection mainly by Listeria monocytogenes, and although the frequency of infection is low in Listeria infection, it has a high mortality rate of 20-40% in the United States. In healthy people, it causes diarrhea, fever, headache, muscle pain and gastroenteritis, and the incubation period is short. It can cause sepsis and meningitis in patients with weakened immune function, pregnant women, the elderly, and infants. Pregnant women are also about 20 times more likely to contract Listeria than other healthy adults and cause miscarriages or stillbirths. In addition, in the case of listeric meningitis, the fatality rate is about 70%, the fatality rate of sepsis is about 50%, and in the case of pregnancy or newborns, the fatality rate is about 80%. It can be treated with antibiotics, but because Listeria bacteria are parasitic in cells, antibiotics must penetrate into cells for efficacy to appear, making it difficult to treat. Contamination prevention and removal is the best method.

한편, 박테리오파지(bacteriophage)는 특정 세균을 감염시켜 감염된 세균의 성장을 억제하고 저해하는 세균 특이적 바이러스를 의미한다. 박테리오파지는 박테리아에 감염(infection)한 후 박테리아 세포 내부에서 증식을 하고, 증식 후 자손 박테리오파지들이 박테리아 밖으로 나올 때 숙주인 박테리아의 세포벽을 파괴하는 방식으로 박테리아를 사멸시키는 능력을 갖고 있다. 박테리오파지의 박테리아 감염 방식은 매우 특이성이 높아서 특정 박테리아에 감염할 수 있는 박테리오파지의 종류는 일부로 한정된다. 즉, 특정 박테리오파지는 특정 범주의 박테리아에만 감염할 수 있고 이로 인하여 특정 박테리오파지는 특정 박테리아만을 사멸시키며 다른 박테리아에는 영향을 주지 않는다. 따라서 최근 세균성 질환의 대처 방안으로 박테리오파지의 활용이 크게 주목을 받고 있다. 자연 친화적 방식의 선호로 인하여 박테리오파지에 대한 관심은 어느 때보다 높다고 할 수 있으며 기존 항생제의 대체 물질로의 개발 가능성이 부각되면서 다시 박테리오파지가 항-박테리아제로 주목을 받고 있다.On the other hand, bacteriophage (bacteriophage) refers to a bacteria-specific virus that inhibits and inhibits the growth of the infected bacteria by infecting a specific bacteria. Bacteriophages proliferate inside bacterial cells after infection (infection) with bacteria, and when progeny bacteriophages come out of the bacteria after proliferation, they have the ability to kill bacteria by destroying the cell wall of the host bacteria. The bacterial infection method of bacteriophages is very specific, so the types of bacteriophages that can infect specific bacteria are limited to some. That is, a specific bacteriophage can only infect a specific category of bacteria, thereby killing only a specific bacteriophage and not affecting other bacteria. Therefore, the use of bacteriophages as a countermeasure against bacterial diseases has recently received a lot of attention. Due to the preference for nature-friendly methods, interest in bacteriophages can be said to be higher than ever, and as the possibility of development as an alternative to existing antibiotics is highlighted, bacteriophages are again attracting attention as anti-bacterial agents.

이에 본 발명자들은 박테리오파지를 기존 항생제의 대체 물질로 활용하기 위하여, 리스테리아균 특이 박테리오파지를 분리하였고, 분리된 박테리오파지가 리스테리아균을 선택적으로 사멸시킬 수 있음을 확인함으로써 본 발명을 완성하게 되었다. Accordingly, the present inventors have isolated Listeria-specific bacteriophages in order to utilize bacteriophages as substitutes for existing antibiotics, and completed the present invention by confirming that the isolated bacteriophages can selectively kill Listeria bacteria.

따라서 본 발명의 목적은 리스테리아균 특이적인 사멸능을 갖는, 서열번호 1로 표시되는 염기서열로 이루어진 박테리오파지 OPT-LM1(수탁번호 KFCC11839P)을 제공하는 것이다. Therefore, it is an object of the present invention to provide a bacteriophage OPT-LM1 (Accession No. KFCC11839P) consisting of the nucleotide sequence represented by SEQ ID NO: 1, having a Listeria-specific killing ability.

본 발명의 다른 목적은 상기 박테리오파지 OPT-LM1을 포함하는 항생용 조성물을 제공하는 것이다. Another object of the present invention is to provide an antibiotic composition comprising the bacteriophage OPT-LM1.

본 발명의 또 다른 목적은 상기 박테리오파지 OPT-LM1을 포함하는 사료 첨가용 조성물, 사료, 소독제 및 세척제를 제공하는 것이다. Another object of the present invention is to provide a composition, feed, disinfectant and cleaning agent for addition to feed containing the bacteriophage OPT-LM1.

본 발명의 또 다른 목적은 상기 박테리오파지 OPT-LM1을 개체에 투여하는 단계를 포함하는 리스테리아균에 의한 감염성 질병의 예방 또는 치료 방법을 제공하는 것이다. Another object of the present invention is to provide a method for preventing or treating an infectious disease caused by Listeria, comprising administering the bacteriophage OPT-LM1 to an individual.

상기 목적을 달성하기 위하여, 본 발명은 리스테리아균에 특이적인 사멸능을 갖는, 서열번호 1로 표시되는 염기서열로 이루어진 박테리오파지 OPT-LM1(수탁번호 KFCC11839P)을 제공한다. In order to achieve the above object, the present invention provides a bacteriophage OPT-LM1 (Accession No. KFCC11839P) consisting of the nucleotide sequence represented by SEQ ID NO: 1, having a specific killing ability for Listeria bacteria.

또한 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는 항생용 조성물을 제공한다. The present invention also provides an antibiotic composition comprising the bacteriophage OPT-LM1.

또한 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는 사료 첨가용 조성물을 제공한다. The present invention also provides a composition for feed addition comprising the bacteriophage OPT-LM1.

또한 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는 사료를 제공한다.The present invention also provides a feed comprising the bacteriophage OPT-LM1.

또한 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는 소독제를 제공한다. The present invention also provides a disinfectant comprising the bacteriophage OPT-LM1.

또한 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는 세척제를 제공한다. The present invention also provides a cleaning agent comprising the bacteriophage OPT-LM1.

또한 본 발명은 상기 박테리오파지 OPT-LM1을 개체에 투여하는 단계를 포함하는 리스테리아균에 의한 감염성 질병의 예방 또는 치료 방법을 제공한다. The present invention also provides a method for preventing or treating an infectious disease caused by Listeria, comprising administering the bacteriophage OPT-LM1 to an individual.

본 발명에 따른 박테리오파지 OPT-LM1은 리스테리아균에 대한 특이성이 매우 높고, 리스테리아균에 감염하여 리스테리아균 내에서 증식함으로써 용균 활성이 우수하며, 물리화학적 자극에 강하다는 장점을 가지고 있다. 또한 본 발명의 박테리오파지 OPT-LM1은 사람, 동물, 식물 등 세균 외의 다른 숙주에는 감염되지 않으므로, 항생제의 오남용으로 인한 항생제 내성균의 문제점, 식품 내의 항생제 잔류 문제, 광범위한 숙주범위의 문제점을 해결할 수 있는바, 항생용 조성물, 사료 첨가용 조성물, 사료, 소독제 또는 세척제 분야에서 다양하게 활용될 수 있다. Bacteriophage OPT-LM1 according to the present invention has a very high specificity to Listeria, has excellent lytic activity by being infected with Listeria and proliferated in Listeria, and has the advantage of being strong in physicochemical stimuli. In addition, the bacteriophage OPT-LM1 of the present invention does not infect other hosts other than bacteria, such as humans, animals, and plants, so it is possible to solve the problems of antibiotic-resistant bacteria due to the misuse of antibiotics, the problem of antibiotic residue in food, and the problem of a wide host range. , can be used in various ways in the field of antibiotic composition, feed additive composition, feed, disinfectant or cleaning agent.

도 1은 본 발명에 따른 박테리오파지 OPT-LM1의 전체 유전자를 분석한 결과를 나타낸 도이다.
도 2는 본 발명에 따른 박테리오파지 OPT-LM1의 형태학적 특성을 확인한 결과를 나타낸 도이다.
도 3은 본 발명에 따른 박테리오파지 OPT-LM1의 리스테리아 모노사이토제네스에 대한 사멸능을 분석한 결과를 나타낸 도이다.
도 4는 본 발명에 따른 박테리오파지 OPT-LM1의 pH 안전성을 확인한 결과를 나타낸 도이다.
도 5는 본 발명에 따른 박테리오파지 OPT-LM1의 온도 안정성을 확인한 결과를 나타낸 도이다.
1 is a view showing the results of analyzing the entire gene of the bacteriophage OPT-LM1 according to the present invention.
Figure 2 is a view showing the results of confirming the morphological characteristics of the bacteriophage OPT-LM1 according to the present invention.
Figure 3 is a diagram showing the results of analyzing the killing ability for Listeria monocytogenes of the bacteriophage OPT-LM1 according to the present invention.
Figure 4 is a view showing the results of confirming the pH safety of the bacteriophage OPT-LM1 according to the present invention.
5 is a view showing the results of confirming the temperature stability of the bacteriophage OPT-LM1 according to the present invention.

이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.

본 발명은 리스테리아균에 특이적인 사멸능을 갖는, 서열번호 1로 표시되는 염기서열로 이루어진 박테리오파지 OPT-LM1(수탁번호 KFCC11839P)을 제공한다. The present invention provides a bacteriophage OPT-LM1 (Accession No. KFCC11839P) consisting of the nucleotide sequence represented by SEQ ID NO: 1, having a specific killing ability for Listeria bacteria.

본 발명의 박테리오파지 OPT-LM1은 하수처리장으로부터 시료를 채취하여 분리한 박테리오파지로서, 본 발명자는 박테리오파지 OPT-LM1으로 명명하고 2019년 9월 27일에 한국미생물보존센터(Korean Culture Center of Microorganisms, 서울, 한국)에 기탁하여, 수탁번호 KFCC11839P를 부여받았다. Bacteriophage OPT-LM1 of the present invention is a bacteriophage isolated by collecting a sample from a sewage treatment plant, and the present inventor named it bacteriophage OPT-LM1 and on September 27, 2019, the Korea Culture Center of Microorganisms (Korean Culture Center of Microorganisms, Seoul, Korea) and was given an accession number KFCC11839P.

본 발명에서, “박테리오파지(bacteriophage)”는 특정 세균에 감염하여 당해 세균의 성장을 억제하고 저해하는 세균 특이적 바이러스로, 단일 혹은 이중 사슬의 DNA 또는 RNA를 유전 물질로 포함하는 바이러스를 의미한다. In the present invention, “bacteriophage” is a bacteria-specific virus that infects a specific bacteria and inhibits and inhibits the growth of the bacteria, and refers to a virus containing single or double-stranded DNA or RNA as a genetic material.

본 발명에서, “리스테리아균”은 통성혐기성 그람양성 간균으로서, 편모 운동을 하는 균을 의미한다. In the present invention, "Listeria" is a facultative anaerobic Gram-positive bacillus, and refers to a bacteria that exhibits flagellar movement.

본 발명에서, 상기 리스테리아균은 리스테리아 모노사이토제네스(Listeria monocytogenes), 리스테리아 이바노비(Listeria ivanovii), 리스테리아 이노쿠아(Listeria innocua), 리스테리아 웰쉬메리(Listeria welshimeri), 리스테리아 시일리게리(Listeria seeligeri) 및 리스테이라 그라이(Listeria grayi)로 이루어진 군에서 선택된 1종 이상인 것이 바람직하며, 더욱 바람직하게는 리스테리아 모노사이토제네스이나, 이에 제한되지 않는다. In the present invention, the Listeria bacteria is Listeria monocytogenes ( Listeria monocytogenes ), Listeria Ivanovii ( Listeria ivanovii ), Listeria innocua ( Listeria innocua ), Listeria welshimeri ( Listeria welshimeri ), Listeria seeligeri ( Listeria seeligeri ) It is preferable that at least one selected from the group consisting of Listeria grayi , and more preferably Listeria monocytogenes, but is not limited thereto.

즉, 상기 박테리오파지 OPT-LM1은 리스테리아균, 특히 리스테리아 모노사이토제네스에 대해 용균 활성이 탁월하다. That is, the bacteriophage OPT-LM1 has excellent lytic activity against Listeria bacteria, particularly Listeria monocytogenes.

또한, 상기 박테리오파지 OPT-LM1은 62.5 내지 68.75 nm의 크기로 정이십면체의 머리와 짧은 꼬리가 있는 형태인 포도비리대(Podoviridae)에 속한다. 상기 박테리오파지 OPT-LM1은 리스테리아균에 대한 항균능뿐만 아니라, 열 및 pH에 대한 안정성이 우수한 특성을 가지고 있다. 보다 상세하게는 상기 박테리오파지 OPT-LM1은 pH 4 내지 11의 범위에서 안정하며, 특히, pH 5 내지 10의 범위에서는 2시간 동안 안정한 것이 바람직하나 이에 제한되지 않는다. 또한 상기 박테리오파지 OPT-LM1은 온도 40℃ 내지 60℃의 범위에서 60분까지 모두 안정하나, 이에 제한되지 않는다. In addition, the bacteriophage OPT-LM1 belongs to the podoviridae ( Podoviridae ) in the form of an icosahedral head and a short tail with a size of 62.5 to 68.75 nm. The bacteriophage OPT-LM1 has not only antibacterial activity against Listeria but also excellent stability against heat and pH. More specifically, the bacteriophage OPT-LM1 is stable in the range of pH 4 to 11, in particular, in the range of pH 5 to 10, it is preferably stable for 2 hours, but is not limited thereto. In addition, the bacteriophage OPT-LM1 is all stable up to 60 minutes in a temperature range of 40 ℃ to 60 ℃, but is not limited thereto.

본 발명의 박테리오파지 OPT-LM1은 서열번호 1로 표시되는 염기서열 전체 유전자의 전체 또는 일부로서 포함할 수 있다. 또한, 본 발명의 박테리오파지 OPT-LM1은 서열번호 1로 표시되는 염기서열, 및 상기 염기서열의 기능적 동등물로 이루어질 수 있다. 상기 기능적 동등물이란 염기서열의 변형, 치환의 결과, 상기 서열번호 1로 표시되는 염기서열과 적어도 70%이상, 바람직하게는 80% 이상, 더욱 바람직하게는 90% 이상, 더더욱 바람직하게는 95% 이상의 서열 상동성을 갖는 것으로, 서열번호 1로 표시되는 염기서열과 실질적으로 동질의 생리활성을 나타내는 서열을 의미한다.The bacteriophage OPT-LM1 of the present invention may include all or a part of the entire gene of the nucleotide sequence represented by SEQ ID NO: 1. In addition, the bacteriophage OPT-LM1 of the present invention may consist of a nucleotide sequence represented by SEQ ID NO: 1, and a functional equivalent of the nucleotide sequence. The functional equivalent means at least 70% or more, preferably 80% or more, more preferably 90% or more, even more preferably 95% of the nucleotide sequence represented by SEQ ID NO: 1 as a result of modification and substitution of the nucleotide sequence. As having the above sequence homology, it refers to a sequence that exhibits substantially the same physiological activity as the nucleotide sequence represented by SEQ ID NO: 1.

상기와 같은 리스테리아균 특이적 용균활성, 내산성, 내염기성 및 내열성은 본 발명의 박테리오파지 OPT-LM1을 리스테리아균에 의한 감염성 질병의 예방 및 치료용 조성물, 및 상기 박테리오파지 OPT-LM1을 유효성분으로 포함하는 다양한 제품에 적용함에 있어, 다양한 온도 및 pH 범위의 적용이 가능하게 한다. The Listeria-specific lytic activity, acid resistance, basic resistance and heat resistance as described above include the bacteriophage OPT-LM1 of the present invention for the prevention and treatment of infectious diseases caused by Listeria bacteria, and the bacteriophage OPT-LM1 comprising the bacteriophage OPT-LM1 as an active ingredient In application to various products, it enables the application of various temperature and pH ranges.

또한, 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는, 항생용 조성물을 제공한다. In addition, the present invention provides an antibiotic composition comprising the bacteriophage OPT-LM1.

본 발명에서, “항생용 조성물”은 약제 형태로 개체에 제공되어 균을 사멸시킬 수 있는 제제를 의미하며, 방부제, 살균제, 항생제 및 항균제를 총칭하는 것이다.In the present invention, “antibiotic composition” refers to an agent that is provided to an individual in the form of a drug to kill bacteria, and is a generic term for preservatives, bactericides, antibiotics and antibacterial agents.

본 발명의 박테리오파지 OPT-LM1은 기존 항생제에 비하여 리스테리아균에 대한 특이성이 매우 높으므로, 유익균은 죽이지 않고, 특정 병원균만 사멸시킬 수 있고, 약물 내성 내지 저항성을 유도하지 않아, 기존의 항생 물질에 비하여 제품 수명(life cycling)이 긴 신규 항생제로서 이용될 수 있다. Since the bacteriophage OPT-LM1 of the present invention has very high specificity for Listeria bacteria compared to conventional antibiotics, it does not kill beneficial bacteria, can only kill specific pathogens, and does not induce drug resistance or resistance, compared to conventional antibiotics It can be used as a novel antibiotic with a long life cycle.

또한, 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는, 사료 첨가용 조성물을 제공한다. In addition, the present invention provides a composition for addition to feed, comprising the bacteriophage OPT-LM1.

축산, 수산업에서 사용되는 사료 첨가용 항생제는 질병의 예방 목적으로 사용되고 있는데, 예방 목적의 항생제 투여는 내성균 발생 가능성을 높이고 가축에 잔류하는 항생제가 사람에게 전달될 수 있어서 문제이다. 항생제가 육류를 통해 인체에 흡수되면 항생제 내성을 유발해 질병의 확산을 부를 수도 있다. 또한, 사료에 섞어 먹이는 항생제의 종류가 많고 이는 다제내성균 발생 확률이 높아지는 문제점이 있기 때문에 좀 더 자연 친화적이면서도 기존의 항생제의 사용에서 발생한 문제를 해결할 새로운 사료 첨가용 항생물질로서 본 발명의 상기 박테리오파지 OPT-LM1을 이용할 수 있다.Antibiotics for addition to feed used in livestock and fisheries are used for the purpose of preventing diseases. When antibiotics are absorbed into the body through meat, they can lead to antibiotic resistance, which can lead to the spread of diseases. In addition, since there are many types of antibiotics mixed with feed and there is a problem that the probability of occurrence of multidrug-resistant bacteria increases, the bacteriophage OPT of the present invention as a new antibiotic for feed addition that is more environmentally friendly and solves problems caused by the use of existing antibiotics -LM1 can be used.

또한, 본 발명은 상기 사료 첨가용 조성물을 포함하는 사료를 제공할 수 있으며, 본 발명의 사료는 박테리오파지를 사료 첨가제 형태로 따로 제조하여 사료에 혼합시키거나, 사료 제조 시 직접 첨가시켜 제조할 수 있다. 본 발명의 사료 내 박테리오파지는 액상 또는 건조 상태일 수 있으며, 바람직하게는 건조된 분말형태이다. 건조방법은 통풍건조, 자연건조, 분무건조 및 동결건조가 가능하지만, 이에 제한되는 것은 아니다. 본 발명의 박테리오파지는 분말형태로 사료 중량의 0.05 중량% 내지 10 중량%, 바람직하게는 0.1 중량% 내지 2 중량%의 성분비로 혼합될 수 있다. 또한, 상기 사료는 본 발명의 박테리오파지 외에 사료의 보존성을 높일 수 있는 통상의 첨가제들을 추가로 포함할 수 있다.In addition, the present invention may provide a feed comprising the composition for addition to the feed, and the feed of the present invention may be prepared by separately preparing bacteriophages in the form of feed additives and mixing them with the feed, or by directly adding them during feed production. . The bacteriophage in the feed of the present invention may be in a liquid or dry state, preferably in a dried powder form. The drying method may include, but is not limited to, ventilation drying, natural drying, spray drying and freeze drying. The bacteriophage of the present invention may be mixed in a powder form in a component ratio of 0.05% to 10% by weight, preferably 0.1% to 2% by weight of the weight of the feed. In addition, the feed may further include conventional additives that can increase the preservation of the feed in addition to the bacteriophage of the present invention.

본 발명의 사료 첨가용 조성물에는 비병원성의 다른 미생물이 추가로 첨가될 수 있다. 첨가될 수 있는 미생물로는 단백질 분해 효소, 지질 분해효소 및 당 전환 효소를 생산할 수 있는 바실러스 서브틸리스(Bacillus subtilis), 소의 위와 같은 혐기적 조건에서 생리적 활성 및 유기물 분해능이 있는 락토바실러스 균주(Lactobacillus sp.), 동물의 체중을 증가시키며 우유의 산유량을 늘리고 사료의 소화 흡수율을 높이는 효과를 보여주는 아스퍼질러스 오리자에(Aspergillus oryzae) 및 사카로미세스 세레비지에(Saccharomyces cerevisiae)로 구성된 군으로부터 선택될 수 있다.Other non-pathogenic microorganisms may be additionally added to the composition for adding feed of the present invention. Microorganisms that can be added include Bacillus subtilis capable of producing proteolytic enzymes, lipolytic enzymes and sugar converting enzymes, Lactobacillus strains having physiological activity and organic matter decomposition ability under anaerobic conditions such as the stomach of cattle ( Lactobacillus ) sp.), increase the animal's weight, increase milk production, and increase the digestibility and absorption rate of feed Aspergillus oryzae ( Aspergillus oryzae ) and Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) Selected from the group consisting of can be

본 발명의 박테리오파지 OPT-LM1을 포함하는 사료에는 식물성으로는 곡물류, 근과류, 식품가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류, 곡물부산물류 등이 있으며, 동물성으로는 단백질류, 무기물류, 유지류, 광물성류, 단세포 단백질, 동물성 플랑크톤류, 남은 음식물 등이 있으며 이에 제한되는 것은 아니다.The feed containing the bacteriophage OPT-LM1 of the present invention includes grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds, grain by-products, etc. Examples include, but are not limited to, proteins, inorganic materials, oils and fats, minerals, unicellular proteins, zooplankton, and leftovers.

본 발명의 사료 첨가용 조성물에는 품질 저하를 방지하기 위하여 첨가하는 결착제, 유화제, 보존제 등이 포함될 수 있고, 효용 증대를 위하여 사료에 첨가하는 아미노산제, 비타민제, 효소제, 생균제, 향미제, 비단백태질소화합물, 규산염제, 완충제, 착색제, 추출제, 올리고당 등이 포함될 수 있으며, 그 외에도 사료 혼합제 등을 추가로 포함할 수 있다.The composition for feed addition of the present invention may include binders, emulsifiers, preservatives, etc. added to prevent quality deterioration, and amino acids, vitamins, enzymes, probiotics, flavoring agents, non-proteinaceous agents added to feed to increase efficacy A nitrogen compound, a silicate agent, a buffer, a colorant, an extractant, an oligosaccharide, etc. may be included, and in addition, a feed mixture agent and the like may be additionally included.

또한, 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는, 소독제를 제공한다. In addition, the present invention provides a disinfectant comprising the bacteriophage OPT-LM1.

다양한 리스테리아균에 특이적 사멸능을 갖는 본 발명의 박테리오파지 OPT-LM1을 포함하는 소독제는 병원감염을 막기 위한 병원 및 보건용의 소독제로 유용하게 사용될 수 있고 일반 생활 소독제, 식품 및 조리 장소 및 설비의 소독제, 양계장, 축사 등의 건물, 축체, 음수, 깔짚, 난좌, 운반차량, 식기 등의 각종 생육 용품의 소독 등에 사용될 수 있다.The disinfectant containing the bacteriophage OPT-LM1 of the present invention having a specific killing ability against various Listeria bacteria can be usefully used as a disinfectant for hospitals and public health to prevent hospital infection, and can be usefully used as a disinfectant for general life, food and cooking places and facilities. It can be used as a disinfectant, for the disinfection of various growing products such as buildings, livestock, drinking water, litter, egg seats, transport vehicles, tableware, such as poultry farms and livestock houses.

또한, 본 발명은 상기 박테리오파지 OPT-LM1을 포함하는, 세척제를 제공한다.In addition, the present invention provides a cleaning agent comprising the bacteriophage OPT-LM1.

본 발명의 박테리오파지 OPT-LM1은 다양한 리스테리아균에 특이적 사멸능을 가지므로, 상기 리스테리아균에 노출되었거나 노출될 가능성이 있는 가축의 피부 표면 또는 신체 각 부위 등을 세척하는 용도로도 사용될 수 있다.Since the bacteriophage OPT-LM1 of the present invention has a specific killing ability against various Listeria bacteria, it can also be used for washing the skin surface or body parts of livestock exposed or likely to be exposed to the Listeria bacteria.

또한, 본 발명은 상기 박테리오파지 OPT-LM1을 개체에 투여하는 단계를 포함하는, 리스테리아균에 의한 감염성 질병의 예방 또는 치료 방법을 제공한다.In addition, the present invention provides a method for preventing or treating an infectious disease caused by Listeria, comprising administering the bacteriophage OPT-LM1 to an individual.

상기 리스테리아균은 리스테리아 모노사이토제네스(Listeria monocytogenes), 리스테리아 이바노비(Listeria ivanovii), 리스테리아 이노쿠아(Listeria innocua), 리스테리아 웰쉬메리(Listeria welshimeri), 리스테리아 시일리게리(Listeria seeligeri) 및 리스테이라 그라이(Listeria grayi)로 이루어진 군에서 선택된 1종 이상인 것이 바람직하며, 더욱 바람직하게는 리스테리아 모노사이토제네스이나, 이에 제한되지 않는다.The Listeria bacteria are Listeria monocytogenes ( Listeria monocytogenes ), Listeria ivanovii ( Listeria ivanovii ), Listeria innocua ( Listeria innocua ), Listeria welshimeri ( Listeria welshimeri ), Listeria seeligeri ) and Listeria seeligeri ) ( Listeria grayi ) It is preferably at least one selected from the group consisting of, more preferably Listeria monocytogenes, but is not limited thereto.

본 발명의 리스테리아균의 감염으로 인한 질병은 리스테리아 감염증, 식중독, 급성위장염, 말단회장염, 패혈증 또는 수막염일 수 있으나, 이에 제한되지 않는다. The disease caused by the Listeria infection of the present invention may be Listeria infection, food poisoning, acute gastroenteritis, terminal ileitis, sepsis or meningitis, but is not limited thereto.

따라서 본 발명의 방법은 상기 리스테리아균의 감염으로 인한 질병이 발생한 개체 또는 발생 위험이 있는 개체에 박테리오파지 OPT-LM1을 투여하는 단계를 포함한다.Accordingly, the method of the present invention includes administering the bacteriophage OPT-LM1 to an individual having a disease caused by the Listeria infection or an individual at risk of occurrence.

본 발명에서, "개체"는 리스테리아균에 의한 감염성 질병이 발병될 수 있는 모든 개체를 의미하는 것으로 인간을 포함한 포유동물, 가축류 또는 가금류를 포함하나, 이에 제한되는 것은 아니다. In the present invention, "individual" refers to any individual that can develop an infectious disease caused by Listeria, and includes mammals, livestock, or poultry, including humans, but is not limited thereto.

상기 "가축류"는 인간에 의하여 순화, 개량되어 사람과 함께 공동생활을 하는 유용한 동물을 지칭하는 개념으로, 예를 들어, 돼지, 소, 닭, 말, 오리 또는 개 등을 포함하나, 이에 제한되는 것은 아니다.The "livestock" is a concept that refers to useful animals that have been domesticated and improved by humans and live together with humans, for example, including pigs, cattle, chickens, horses, ducks or dogs, but is not limited thereto. it is not

상기 "가금류"는, 가축 중 조류에 속하는 동물을 총칭하여 이르는 개념으로, 예를 들어, 닭, 오리, 꿩, 메추리, 타조, 거위, 앵무새 또는 칠면조 등을 포함하나, 이에 제한되는 것은 아니다.The "poultry" is a concept that collectively refers to animals belonging to birds among livestock, and includes, for example, chickens, ducks, pheasants, quails, ostriches, geese, parrots or turkeys, but is not limited thereto.

본 발명의 방법에서 상기 박테리오파지 OPT-LM1 또는 이를 포함하는 조성물은 약학적 제제의 형태로 개체에 투여되거나, 가축의 사료 또는 음용수에 혼합하여 이를 섭식시키는 방법을 통해 투여될 수 있다.In the method of the present invention, the bacteriophage OPT-LM1 or a composition comprising the same may be administered to an individual in the form of a pharmaceutical preparation, or mixed with livestock feed or drinking water and administered through a method of feeding it.

본 발명의 방법에서 상기 박테리오파지 OPT-LM1 또는 이를 포함하는 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있으며, 구체적으로, 구강, 직장, 국소, 정맥 내, 복강 내, 근육 내, 동맥 내, 경피, 비측 내, 흡입 등을 통해 통상적인 방식으로 투여될 수 있다.In the method of the present invention, the administration route of the bacteriophage OPT-LM1 or a composition comprising the same may be administered through various routes, either oral or parenteral, as long as it can reach the target tissue, and specifically, oral, rectal, topical, intravenous It can be administered in a conventional manner via intraperitoneal, intraperitoneal, intramuscular, intraarterial, transdermal, intranasal, inhalation and the like.

본 발명의 방법에 투여되는 상기 박테리오파지 OPT-LM1의 적합한 총 1일 사용량은 올바른 의학적 판단범위 내에서 처치에 의해 결정될 수 있다는 것은 당업자에게 자명한 일이다. 특정 개체에 대한 구체적인 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다.It is apparent to those skilled in the art that the suitable total daily amount of the bacteriophage OPT-LM1 administered in the method of the present invention can be determined by treatment within the scope of correct medical judgment. A specific therapeutically effective amount for a specific individual may be determined with the type and degree of response to be achieved, the patient's age, weight, general health, sex and diet, administration time, administration route and secretion rate of the composition, treatment period, and specific composition. It is preferable to apply differently depending on various factors including drugs used or concurrently used and similar factors well known in the medical field.

본 명세서에서 달리 정의되지 않은 용어들은 본 발명이 속하는 기술 분야에서 통상적으로 사용되는 의미를 갖는 것이다. Terms not defined otherwise herein have the meanings commonly used in the technical field to which the present invention pertains.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples.

실시예 1. 신규한 박테리오파지의 분리 및 배양Example 1. Isolation and culture of novel bacteriophages

1.1 박테리오파지의 스크리닝 및 단일 박테리오파지의 분리 1.1 Screening of bacteriophages and isolation of single bacteriophages

리스테리아 모노사이토제네스에 특이적인 특이적인 박테리오파지를 스크리닝 및 분리하기 위해서 용균반 분석을 진행하였다. 시료는 박테리오파지가 존재할 것으로 예상되는 하수처리장으로부터 채취하였으며, 박테리오파지 분리에 사용된 리스테리아 모노사이토제네스는 ㈜옵티팜에서 채취한 야외 시료로부터 분리 동정된 것을 사용하였다.In order to screen and isolate a specific bacteriophage specific to Listeria monocytogenes, a lysate analysis was performed. The sample was collected from a sewage treatment plant where bacteriophages are expected to exist, and Listeria monocytogenes used for bacteriophage separation was isolated and identified from outdoor samples collected by Optipharm Co., Ltd.

구체적으로, 채취한 시료를 균질화 한 후 리스테리아 모노사이토제네스와 함께 35℃에서 24시간 동안 배양하였다. 상기 배양액을 3,000 rpm으로 20분간 원심분리한 후, 상등액을 공극(pore) 크기가 0.2 μm인 필터를 이용하여 여과하여 시료 여과액을 얻었다. Specifically, after homogenizing the collected sample, it was incubated with Listeria monocytogenes at 35° C. for 24 hours. After centrifuging the culture solution at 3,000 rpm for 20 minutes, the supernatant was filtered using a filter having a pore size of 0.2 μm to obtain a sample filtrate.

전배양된 리스테리아 모노사이토제네스 150 μL를 취해서 멸균된 튜브에 넣고 3 mL의 TSB + 0.6% 효모 추출물 탑 아가 [TSB배지 (트립톤 17 g/L; 대두분 3 g/L; 포도당 2.5 g/L; K2HPO4 2.5 g/L; NaCl 10 g/L; 효모 추출물 6 g/L) + 0.6% 아가]를 첨가하여 잘 혼합한 후 미리 만들어 둔 2% TSB + 0.6% 효모 추출물 아가 플레이트에 중층하였다. 이를 실온에서 30분간 방치한 후 상기 시료 여과액을 각각 10 μL씩 점적하고, 다시 실온에서 30분간 방치한 후 35℃에서 24시간 동안 배양하여 박테리오파지의 유무를 확인하였다. Take 150 μL of pre-cultured Listeria monocytogenes, put it in a sterile tube, and put 3 mL of TSB + 0.6% yeast extract top agar [TSB medium (tryptone 17 g/L; soy flour 3 g/L; glucose 2.5 g/L) ; K 2 HPO 4 2.5 g/L; NaCl 10 g/L; yeast extract 6 g/L) + 0.6% agar] was added and mixed well, and then layered on a pre-made 2% TSB + 0.6% yeast extract agar plate. did After leaving this at room temperature for 30 minutes, 10 μL of each of the sample filtrates was added dropwise, and then left at room temperature for 30 minutes, and then cultured at 35° C. for 24 hours to confirm the presence or absence of bacteriophages.

박테리오파지의 존재를 확인한 시료로부터 박테리오파지를 순수 분리하기 위해서 소프트 아가 오버레이(soft agar overlay)법을 이용하였다. 박테리오파지가 존재하는 것으로 확인된 시료를 식염수로 적절히 희석하여 각 희석단의 시료 희석액 100 μL를 취하고, 대상 세균(리스테리아 모노사이토제네스) 배양액 150 μL에 혼합한 후 TSB + 0.6% 효모 추출물 탑 아가를 3 mL 첨가하여 잘 혼합한 뒤, 미리 만들어 둔 2% TSB + 0.6% 효모 추출물 아가 플레이트에 중층하여 방치한 후 35℃에서 24시간 배양하였다. 배양한 각 플레이트에서 형성된 용균반을 확인한 후 선택하여 400 μL의 SM 완충액(NaCl 5.8 g/L; MgSO47H2O 2 g/L; 1M Tris-HCl (pH7.5) 50 mL)에 현탁하고, 실온에서 4시간동안 방치하였다. 상기 박테리오파지 액 100 μL를 TSB + 0.6% 효모 추출물 탑 아가와 세균배양액 500 μL와 혼합한 뒤 150 mm 지름의 TSB + 0.6% 효모 추출물 아가 플레이트에 분주하여 중층한 후 완전히 용균이 일어날 때까지 35℃에서 배양하였다. 배양이 종료된 후, TSB + 0.6% 효모 추출물 아가 플레이트에 15 mL의 SM 완충액을 가하고 실온에서 4시간동안 천천히 교반하면서 박테리오파지 용액을 회수한 후 3,000 rpm으로 20분간 원심분리하여 상등액만 취하고 이를 0.2 μm 필터로 여과하여 최종 박테리오파지 용액을 회수하였다.A soft agar overlay (soft agar overlay) method was used to purely separate the bacteriophage from the sample confirming the presence of the bacteriophage. The sample confirmed to have bacteriophages is appropriately diluted with saline, and 100 µL of the sample dilution from each dilution stage is taken, mixed with 150 µL of the target bacterial (Listeria monocytogenes) culture, and TSB + 0.6% yeast extract top agar is added to 3 mL was added and mixed well, layered on a pre-made 2% TSB + 0.6% yeast extract agar plate, left to stand, and incubated at 35°C for 24 hours. After checking the plaques formed on each cultured plate, select and suspend in 400 μL of SM buffer (NaCl 5.8 g/L; MgSO 4 7H 2 O 2 g/L; 1M Tris-HCl (pH7.5) 50 mL) , and left at room temperature for 4 hours. 100 μL of the bacteriophage solution was mixed with 500 μL of TSB + 0.6% yeast extract top agar culture medium, and then dispensed and layered on a 150 mm diameter TSB + 0.6% yeast extract agar plate at 35° C. until complete lysis occurs. cultured. After the culture was completed, 15 mL of SM buffer was added to the TSB + 0.6% yeast extract agar plate, and the bacteriophage solution was recovered while stirring slowly at room temperature for 4 hours. Then, centrifuged at 3,000 rpm for 20 minutes to take only the supernatant and 0.2 μm The final bacteriophage solution was recovered by filtration with a filter.

1.2 박테리오파지의 대량 배양 및 정제1.2 Mass culture and purification of bacteriophages

상기 실시예 1.1에서 확인한 리스테리아 모노사이토제네스 특이적 박테리오파지를 대량 배양하기 위하여, 실시예 1.1에서 회수한 최종 박테리오파지 배양액을 1.0x108 PFU/mL로 희석한 후 전배양된 리스테리아 모노사이토제네스 1.0x109 CFU/mL와 MOI(Multiplicity of infection)를 0.1이 되도록 혼합하여 35℃에서 100 rpm으로 24시간 배양하였다. 배양이 종료된 후 배양액 전량을 6,000 rpm으로 30분간 원심분리하여 상등액을 수득하였고, 이를 0.2 μm 필터로 여과하여 최종 박테리오파지 배양액을 회수하였다. In order to mass-culture the Listeria monocytogenes-specific bacteriophage identified in Example 1.1, the final bacteriophage culture solution recovered in Example 1.1 was diluted to 1.0x10 8 PFU/mL and then pre-cultured Listeria monocytogenes 1.0x10 9 CFU /mL and MOI (Multiplicity of Infection) were mixed to 0.1, and incubated at 35°C at 100 rpm for 24 hours. After the culture was completed, the entire amount of the culture solution was centrifuged at 6,000 rpm for 30 minutes to obtain a supernatant, which was filtered with a 0.2 μm filter to recover the final bacteriophage culture solution.

분리된 박테리오파지를 “박테리오파지 OPT-LM1(Bacteriophage OPT-LM1)”으로 명명하고, 2019년 9월 27일에 한국미생물보존센터(Korean Culture Center of Microorganisms, 서울, 한국)에 기탁하여, 수탁번호 KFCC11839P를 부여받았다. The separated bacteriophage was named “Bacteriophage OPT-LM1” and deposited at the Korean Culture Center of Microorganisms (Seoul, Korea) on September 27, 2019, and accession number KFCC11839P has been granted

실시예 2. 박테리오파지 OPT-LM1의 전체 유전자 분석Example 2. Whole Gene Analysis of Bacteriophage OPT-LM1

박테리오파지 OPT-LM1의 전체 유전자를 분석하기 위해, 박테리오파지 OPT-LM1 배양액에 20 mM EDTA, 50 μg/mL의 프로테나아제 K, 0.5%(w/v) SDS를 가한 후, 50℃에서 1시간 동안 정치하였다. 동량의 페놀-클로로포름-이소프로필 알코올(25:24:1)과 혼합한 후 실온에서 12,000 rpm으로 10분간 원심분리하여 상등액을 회수하였다. 회수된 상등액을 동일 부피의 페놀-클로로포름-이소프로필 알코올(25:24:1)과 혼합하여 실온에서 12,000 rpm으로 10분간 원심분리한 후 상등액을 회수하고, 상기 상등액에 3 M 소듐 아세테이트를 전체 부피의 10%(v/v)가 되도록 가한 후 혼합하였다. 여기에 2배 부피의 차가운 95% 에탄올을 가하여 혼합한 뒤 -20℃에서 1시간 동안 정치하였다. 반응이 끝난 후 0℃에서 10분간 12,000 rpm으로 원심분리하여 침전물을 획득하였고, 차가운 70% 에탄올로 2 회 세척한 뒤 에탄올을 완전히 제거하여 DNA 펠렛을 회수하였다. 회수한 펠렛을 최종 부피가 50 μL가 되도록 TE 완충액(Tris-EDTA, pH8.0)에 용해시킨 후 DNA 농도를 측정하였다. 전체 유전자 분석을 위해 PacBioRSll 를 이용하여 유전자 시퀀싱을 시행하였다(마크로젠, 한국). 시퀀싱 결과로 얻은 박테리오파지 OPT-LM1의 유전자 맵은 도 1에 나타내었다.To analyze the entire gene of the bacteriophage OPT-LM1, 20 mM EDTA, 50 μg/mL of proteinase K, 0.5% (w/v) SDS was added to the bacteriophage OPT-LM1 culture medium, and then at 50° C. for 1 hour. was political. After mixing with the same amount of phenol-chloroform-isopropyl alcohol (25:24:1), the supernatant was recovered by centrifugation at 12,000 rpm at room temperature for 10 minutes. The recovered supernatant was mixed with the same volume of phenol-chloroform-isopropyl alcohol (25:24:1) and centrifuged at 12,000 rpm at room temperature for 10 minutes to recover the supernatant, and 3 M sodium acetate was added to the supernatant to the total volume. 10% (v/v) of the mixture was added and then mixed. Two-fold volume of cold 95% ethanol was added thereto, mixed, and left at -20°C for 1 hour. After the reaction was completed, the precipitate was obtained by centrifugation at 12,000 rpm at 0° C. for 10 minutes, washed twice with cold 70% ethanol, and then the ethanol was completely removed to recover the DNA pellet. The recovered pellet was dissolved in TE buffer (Tris-EDTA, pH8.0) to a final volume of 50 μL, and then the DNA concentration was measured. For whole gene analysis, gene sequencing was performed using PacBioRSll (Macrogen, Korea). The gene map of the bacteriophage OPT-LM1 obtained as a result of the sequencing is shown in FIG. 1 .

도 1에 나타낸 바와 같이, 박테리오파지 OPT-LM1의 전체 유전자 크기는 13,843 bp이며, GC함량이 33.2%, ORF는 14개임을 확인하였다. 분석한 박테리오파지 OPT-LM1의 전체 유전자 서열을 서열번호 1로 나타내었다. As shown in Figure 1, the total gene size of the bacteriophage OPT-LM1 was 13,843 bp, GC content was 33.2%, ORF was confirmed that 14. The entire gene sequence of the analyzed bacteriophage OPT-LM1 is shown in SEQ ID NO: 1.

실시예 3. 박테리오파지 OPT-LM1의 형태학적 특성 Example 3. Morphological Characteristics of Bacteriophage OPT-LM1

박테리오파지 OPT-LM1의 형태학적 특성을 알아보기 위해, 배양액을 0.01% 젤라틴 용액에 희석하여 2.5% 글루타르알데하이드(glutaraldehyde) 용액으로 고정하였다. 이를 탄소 코팅 운모 플레이트(carbon-coated mica plate)(ca. 2.5 x 2.5 mm)에 적가한 후, 10분간 적응시켜 멸균증류수로 세척하였다. 이를 구리 격자(copper grid)에 끼워 2% 우라닐 아세테이트(Uranyl acetate)에서 30초 내지 60초간 염색하고 건조시킨 후, 투과전자현미경(Tecnai G2 Spirit Twin, Bio-Transmission electron microscope, 120 kV, 120,000~400,000)으로 관찰하였다. 그 결과를 도 2에 나타내었다.To investigate the morphological characteristics of the bacteriophage OPT-LM1, the culture medium was diluted in 0.01% gelatin solution and fixed with 2.5% glutaraldehyde solution. After this was added dropwise to a carbon-coated mica plate (ca. 2.5 x 2.5 mm), it was acclimatized for 10 minutes and washed with sterile distilled water. This was put on a copper grid, dyed in 2% uranyl acetate for 30 to 60 seconds, dried, and then dried under a transmission electron microscope (Tecnai G 2 Spirit Twin, Bio-Transmission electron microscope, 120 kV, 120,000). ~400,000) was observed. The results are shown in FIG. 2 .

도 2에 나타낸 바와 같이, 박테리오파지 OPT-LM1은 62.5 nm 내지 68.75 nm의 크기로, 정이십면체의 머리와 짧은 꼬리가 있는 형태인 포도비리대(Podoviridae)에 속함을 확인하였다. As shown in Figure 2, the bacteriophage OPT-LM1 has a size of 62.5 nm to 68.75 nm, and it was confirmed that it belongs to the form of an icosahedral head and short tail ( Podoviridae ).

실시예 4. 박테리오파지 OPT-LM1의 다양한 세균에 대한 감염성 및 사멸능 조사 Example 4. Investigation of the infectivity and killing ability of various bacteria of the bacteriophage OPT-LM1

박테리오파지 OPT-LM1이 다양한 세균에 대하여 용균 활성을 나타내는지 확인하기 위하여 ㈜옵티팜에서 분리하여 보유하고 있는 균주와 미생물 자원센터 등에서 분양받은 균주를 대상으로 소프트 아가 오버레이법을 통해서 감염성을 확인하였다. In order to confirm whether the bacteriophage OPT-LM1 exhibits lytic activity against various bacteria, the infectivity was confirmed through the soft agar overlay method for the strains isolated and owned by Optipharm and the strains distributed from the microbial resource center.

그 결과를 표 1 및 표 2에 나타내었다. The results are shown in Tables 1 and 2.

Figure 112020074301012-pat00001
Figure 112020074301012-pat00001

Figure 112020074301012-pat00002
Figure 112020074301012-pat00002

표 1에 나타낸 바와 같이, 리스테리아 모노사이토제네스 35개 균주를 대상으로 박테리오파지 OPT-LM1은 91%(32개 균주)의 용균 활성을 보여 리스테리아 모노사이토제네스에 뛰어난 용균 활성을 가지는 것을 확인하였다. As shown in Table 1, it was confirmed that the bacteriophage OPT-LM1 for 35 strains of Listeria monocytogenes showed a lytic activity of 91% (32 strains) and had excellent lytic activity on Listeria monocytogenes.

표 2에 나타낸 바와 같이, 리스테리아 모노사이토제네스 및 다른 미생물을 대상으로 감수성 조사를 수행한 결과, 박테리오파지 OPT-LM1은 리스테리아 모노사이토제네스에 특이적인 용균활성을 나타내는 것을 확인하였다. As shown in Table 2, as a result of performing a sensitivity study on Listeria monocytogenes and other microorganisms, it was confirmed that the bacteriophage OPT-LM1 exhibited a specific lytic activity for Listeria monocytogenes.

또한 박테리오파지 OPT-LM1의 리스테리아 모노사이토제네스에 대한 사멸능을 분석하였다. 구체적으로, 600 nm에서 흡광도가 약 0.5가 되게 세균 배양액을 10 mL 준비하였다. 세균 배양액에 농도가 1.0x108 PFU/mL 되는 박테리오파지액을 1 mL 넣어 MOI 1로 접종한 실험군과 박테리오파지액을 넣지 않은 시료를 대조군으로 하여 실험을 진행하였다. 18℃ 및 35℃에서 20시간 동안 배양하며 2시간, 4시간, 8시간, 12시간, 20시간 마다 600 nm에서의 흡광도를 측정하였다. 박테리오파지 OPT-LM1을 이용한 리스테리아 모노사이토제네스에 대한 사멸능력의 분석 결과는 표 3 및 도 3에 나타내었다. In addition, the killing ability for Listeria monocytogenes of the bacteriophage OPT-LM1 was analyzed. Specifically, 10 mL of a bacterial culture was prepared so that the absorbance at 600 nm was about 0.5. The experiment was carried out with the experimental group inoculated at MOI 1 and the sample not containing the bacteriophage solution as a control group by adding 1 mL of a bacteriophage solution having a concentration of 1.0x10 8 PFU/mL to the bacterial culture medium. Incubated at 18°C and 35°C for 20 hours, absorbance at 600 nm was measured every 2 hours, 4 hours, 8 hours, 12 hours, and 20 hours. The analysis results of the killing ability for Listeria monocytogenes using the bacteriophage OPT-LM1 are shown in Table 3 and FIG.

Figure 112020074301012-pat00003
Figure 112020074301012-pat00003

표 3 및 도 3에 나타낸 바와 같이, 박테리오파지 OPT-LM1을 첨가하지 않은 대조군의 경우 20시간 후 600 nm에서 흡광도가 18℃ 및 35℃에서 각각 2.85, 3.61로 나타나 세균이 증식한 것을 확인할 수 있다. 반면, 박테리오파지 OPT-LM1을 첨가한 실험군의 경우, 초기 흡광도에 비해 20시간 후의 600 nm에서 흡광도가 18℃ 및 35℃에서 각각 0.17, 0.01로 감소한 것을 통해 세균이 효과적으로 사멸된 것을 알 수 있다. 상기 결과는 박테리오파지 OPT-LM1이 리스테리아 모노사이토제네스에 대한 사멸능이 우수하다는 것을 의미한다. As shown in Table 3 and FIG. 3, in the case of the control group that did not add the bacteriophage OPT-LM1, the absorbance at 600 nm after 20 hours was 2.85 and 3.61 at 18° C. and 35° C., respectively, confirming that the bacteria proliferated. On the other hand, in the case of the experimental group to which the bacteriophage OPT-LM1 was added, the absorbance at 600 nm after 20 hours compared to the initial absorbance was reduced to 0.17 and 0.01 at 18 ° C and 35 ° C, respectively, it can be seen that the bacteria were effectively killed. The result means that the bacteriophage OPT-LM1 has excellent killing ability against Listeria monocytogenes.

실시예 5. 박테리오파지 OPT-LM1의 pH 안정성 조사 Example 5. Investigation of pH stability of bacteriophage OPT-LM1

박테리오파지 OPT-LM1의 pH에 대한 안정성을 확인하기 위하여, 다양한 pH범위(pH 4, 5, 6, 7, 8, 9, 10, 11)에서 박테리오파지의 수를 측정하였다. 소듐 아세테이트 완충액, 소듐 포스페이트 완충액, Tris-HCl을 이용하여 각각의 pH에 맞게 조제한 후 990 μL로 분주하여 준비하였다. 박테리오파지 OPT-LM1 배양액을 5.0x109 PFU/mL가 되도록 준비한 다음 배양액을 10 μL씩 취하여 pH에 맞게 조제한 각각의 완충액에 첨가하여 2 시간 동안 상온에서 방치하였다. 방치 후 각 반응액을 단계 희석하여 소프트 아가 오버레이법에 의한 역가 측정을 수행한 결과를 도 4에 나타내었다.In order to confirm the stability of the bacteriophage OPT-LM1 for pH, the number of bacteriophages in various pH ranges (pH 4, 5, 6, 7, 8, 9, 10, 11) was measured. Sodium acetate buffer, sodium phosphate buffer, and Tris-HCl were used to adjust to each pH and prepared by dispensing in 990 μL. Bacteriophage OPT-LM1 culture medium was prepared to be 5.0x10 9 PFU/mL, and then 10 μL of the culture medium was taken and added to each buffer prepared according to pH, and left at room temperature for 2 hours. After standing, each reaction solution was diluted stepwise, and the results of titer measurement by the soft agar overlay method are shown in FIG. 4 .

도 4에 나타낸 바와 같이, 본 발명의 박테리오파지 OPT-LM1은 pH 5 내지 10의 범위에서는 2시간 동안 매우 안정한 것을 확인하였다. 이를 통해 박테리오파지 OPT-LM1은 pH 안정성이 우수한 박테리오파지임을 알 수 있다. As shown in Figure 4, it was confirmed that the bacteriophage OPT-LM1 of the present invention is very stable for 2 hours in the range of pH 5 to 10. Through this, it can be seen that the bacteriophage OPT-LM1 is a bacteriophage with excellent pH stability.

실시예 6. 박테리오파지 OPT-LM1의 열 안정성 조사 Example 6. Thermal stability investigation of bacteriophage OPT-LM1

박테리오파지 OPT-LM1의 열 안정성을 확인하기 위하여, 다양한 온도 범위(40℃, 50℃, 60℃)에서 일정시간 방치 후 박테리오파지의 수를 측정하였다. 보다 구체적으로, 박테리오파지 OPT-LM1 배양액(5.0x108 PFU/mL) 5 mL를 멸균된 튜브에 분주하고 10, 30 및 60분 동안 각 온도에서 방치하였다. 방치 후 각 반응액을 단계 희석하여 소프트 아가 오버레이법에 의한 역가 측정을 수행한 결과를 도 5에 나타내었다. In order to confirm the thermal stability of the bacteriophage OPT-LM1, the number of bacteriophages was measured after leaving for a certain time in various temperature ranges (40 ℃, 50 ℃, 60 ℃). More specifically, 5 mL of the bacteriophage OPT-LM1 culture solution (5.0x10 8 PFU/mL) was dispensed into a sterile tube and left at each temperature for 10, 30 and 60 minutes. After standing, each reaction solution was diluted stepwise, and the results of titer measurement by the soft agar overlay method are shown in FIG. 5 .

도 5에 나타낸 바와 같이, 본 발명의 박테리오파지 OPT-LM1은 40℃ 내지 60℃의 범위에서 안정한 것을 확인하였다. 이를 통해 박테리오파지 OPT-LM1은 내열성이 우수한 박테리오파지임을 알 수 있다. As shown in Figure 5, it was confirmed that the bacteriophage OPT-LM1 of the present invention is stable in the range of 40 ℃ to 60 ℃. Through this, it can be seen that the bacteriophage OPT-LM1 is a bacteriophage with excellent heat resistance.

종합적으로 본 발명자들은 박테리오파지 OPT-LM1이 리스테리아균, 특히 리스테리아 모노사이토제네스에 대한 특이성이 매우 높고, 리스테리아균에 감염하여 리스테리아균 내에서 증식함으로써 용균 활성이 우수하며, 물리화학적 자극에 강하다는 장점을 가지고 있음을 확인하였다. 또한 본 발명의 박테리오파지 OPT-LM1은 사람, 동물, 식물 등 세균 외의 다른 숙주에는 감염되지 않으므로, 항생제의 오남용으로 인한 항생제 내성균의 문제점, 식품 내의 항생제의 잔류문제, 광범위한 숙주범위의 문제점을 해결할 수 있는 장점이 있다. 따라서 본 발명의 박테리오파지 OPT-LM1은 항생용 조성물, 사료 첨가용 조성물, 사료, 소독제 또는 세척제 분야에서 다양하게 활용될 수 있다. Overall, the present inventors have found that the bacteriophage OPT-LM1 has very high specificity for Listeria bacteria, particularly Listeria monocytogenes, and has excellent lytic activity by infecting Listeria bacteria and proliferating in Listeria bacteria, and has strong resistance to physicochemical stimulation. confirmed to have it. In addition, since the bacteriophage OPT-LM1 of the present invention does not infect other hosts other than bacteria such as humans, animals, plants, etc., it is possible to solve the problems of antibiotic-resistant bacteria due to the misuse of antibiotics, the residual problem of antibiotics in food, and the problems of a wide host range. There are advantages. Therefore, the bacteriophage OPT-LM1 of the present invention can be variously used in the field of antibiotic composition, composition for feed addition, feed, disinfectant or detergent.

이하, 제제예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 제제예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 제제예에 의해 제한되는 것으로 해석되지 않는다. Hereinafter, the present invention will be described in more detail through formulation examples. The formulation examples are only for illustrating the present invention, and the scope of the present invention is not to be construed as being limited by the formulation examples.

제제예 1. 사료 첨가용 조성물Formulation Example 1. Composition for adding feed

박테리오파지 OPT-LM1 1x108 PFU/mLBacteriophage OPT-LM1 1x10 8 PFU/mL

비타민 믹스 100 mgVitamin mix 100 mg

미네랄 믹스 100 mg100 mg mineral mix

스테아린산 마그네슘 2 mg2 mg magnesium stearate

통상의 사료 첨가제 제조방법에 따라 상기의 성분들을 혼합하여 제조한다.It is prepared by mixing the above ingredients according to a conventional feed additive manufacturing method.

제제예 2. 소독제 조성물Formulation Example 2. Disinfectant composition

박테리오파지 OPT-LM1 1x109 PFU/mLBacteriophage OPT-LM1 1x10 9 PFU/mL

에탄올 적량appropriate amount of ethanol

멸균 증류수 적량Appropriate amount of sterile distilled water

pH 조절제 적량Appropriate amount of pH adjuster

통상의 소독제 제조방법에 따라 상기의 성분들을 혼합하여 제조한다.It is prepared by mixing the above components according to a conventional disinfectant manufacturing method.

제제예 3. 세척제 조성물Formulation Example 3. Cleaning composition

박테리오파지 OPT-LM1 1x109 PFU/mLBacteriophage OPT-LM1 1x10 9 PFU/mL

에탄올 적량appropriate amount of ethanol

효소 복합물 적량Enzyme Complex Appropriate amount

멸균 증류수 적량Appropriate amount of sterile distilled water

통상의 세척제 제조방법에 따라 상기의 성분들을 혼합하여 제조한다.It is prepared by mixing the above components according to a conventional cleaning agent manufacturing method.

이상, 본 발명내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시 형태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.As mentioned above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. It will be obvious. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.

한국미생물보존센터Korea Microorganism Conservation Center KFCC11839PKFCC11839P 2019092720190927

SEQUENCE LISTING <110> Optipharm.CO.,LTD <120> Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same <130> OTP1_89_P <160> 1 <170> PatentIn version 3.2 <210> 1 <211> 13843 <212> DNA <213> Unknown <220> <223> bacteriophage OPT-LM1 <400> 1 aaaagtcatg cgccacctac tctcccaacg ggtttcccca ttcggtaggg tagggcggac 60 actgtgggta ttttgtccta tagttgggac ttaataccta acagattgca tgacatcgat 120 cattagattt ttgacaacca tatcactgaa ccatacttct ccttcatcga agctttcaat 180 gagtaattta aactgcggtg atttacttat agatttaagt aatattgttc cttgtttatg 240 atctgctgaa ttgataacaa atttcaatgg atattgaggg tcaacatcaa aggaacagtg 300 tagacaacta ttgtctatgt cctcccaaat accaatagtt gtattatcat attcaaccga 360 aaacaggtat ttgctacgct taccacgtga acgcacaaaa ttattattgt ctattaaact 420 agcattttca tatgcaaatt cactaaactt tgttccttca attaaactat aaaaacgtgt 480 tttcttcttc tcttccaaaa atttatcatt actgtaatat tccactaata tttcagggtt 540 atgtttaaag gtgttaaacc tcttttttga ggacggtttt aatttgaaat aattgaagta 600 aggatttgct atactaacgt tattactaat tagcaccatt ttgcaagctc tatatccttc 660 catttctctc attcggttga ctgtttcata taagttcaat aacttattaa cctcatcttt 720 tagataaccg tttgatttcc ctcttgcatc aataataaac tcatcaaaaa taatccattc 780 tacatctgta taattgtttg attttaaatt attttctgtg gaaagattga tataaaaacc 840 gcaaacatca tcatcaatgt aaaattttcc accttttaca tcaaatttta catcttgaaa 900 tctatcttct ttcttcactt tatcgaaaaa catacttata ttatcaaatt ctgaatcata 960 tcttctaaca taaataaatt tatatttttt ctttataaac tgctcgacag cgaaagcagt 1020 ccaaccatat gttttaccta atcccctacc gcctattacc atagataata ggcggttata 1080 tgagatagtt tcataagggg aataataaat ttcattatgc acgtgtttgc actactacaa 1140 gccatttact taattctttt gttgtaaagt ttacttgaca ttgtaatatc tccacattat 1200 cagtgcttct acgggttaaa cggataatcc catgcatgtt tacgggtgga ttgtctggca 1260 tgctagggct tccgtcacca gtagttccat ttaaaacttc aacaaaataa ccagcgctgt 1320 caccaattat aatgcttgta tcaggtctat ctttcatttg aagaaaagcg tcattggtaa 1380 tatagtagtt gattggtctt aaattaccaa acttgtagtt atattgctca gggtgaatta 1440 tttcaccata gtaagaaccg ctttgtttaa acgtccaacg tccaaaccac catttcattg 1500 tatctctgtc aaacctcatt tcacggctca tctctagcaa aggctttaca ctatcatgcc 1560 ttgctagtac ttgtctactt gtccatgtag ggcttaaggg tttaacctct aattcgaaac 1620 tattatctcc tacaggtata ggcataccag ggtaattgat aaccatgcta ttatctaggt 1680 gataaattcc tggttctgtg aagtcaccta aagctttcca attgtcacgt ggtctttttg 1740 cttgaccacc tgcaaccatg taaggaaagt tattactgtc aacacgtgcg ccagatataa 1800 agtgacctaa agaacctctt tgaagcatac cgtaaagaag atgataacgt tttgtaatac 1860 cgccatgtgt aacagcaaat aataaacttc tctttttacg ttttttatca taatataaga 1920 acattccttc gggttcttta aaattatctc taggatagcc tataccgtct gggtaaacta 1980 tatcagggtt taatgaaata ctgctatcca ttgtatcacc tttcattgta gtccaacgat 2040 caatgataag ttgattagat atatcacttg tacccttcat ccaatatact tcataacctg 2100 ttacattatt atctttatca taaagtggta aatgtgtaat accttgcata ggtgttttag 2160 cactttcttc tggtttagta ccgtaatttg ttgtaattct atatttaaat ttatctacac 2220 catttcgaac gtccatgcga tcatagatat aaaatagttg ggttccgtta tcatctgttt 2280 gagttagtct taacagtaat gtatcgctaa aaggttcaaa agtaggtgtg atatattttt 2340 ttaaaaatct ttgtggtgta tagtttgtca aaccctttgc ttcttcaagt gatatagtag 2400 tatttggttt atactcaact tgtaccagct ttcctacacc tgtatgatat aaccatatct 2460 ttaaatcacc atttgtattt ctatctaatc cgattgttgt accatgtccg gcgttaggca 2520 agtgcatgac actaatgaag ttcatggaag gagtaaattc attaatgtaa aaaccttcgg 2580 gtgtttgact atcactctgt gttgtatacc accttcctgt ttcataatcg cattgtatgg 2640 attggtttac agcgtttctt aaacctctaa aactttgaag atataaaggt tcttctcttt 2700 ggaagtcaaa cacattttca atatctaaca aaccatttaa tgcaccttca aaattagagg 2760 taaattcttg aattttagca ttaattttac tttcaaaatc agattgacga atgtctaaac 2820 tatcctcata ctctttcatt aattttttaa gttcgtcaaa taaatctata aatttaccct 2880 ctgcatacca ttcgtttaag atatttctaa catcgttttc cagaccttcg ttttcaagaa 2940 attcaagtaa ttcattccat tttttaacta ggtcactttg tattaaaccc atttcttgca 3000 aatattctac aaaattaatt atcattgttc tatagtcata cacatcagct tctacatcgg 3060 gaagatgaaa attctcaata tatgccgaac ttctaaattt gtgcttgaaa aagtttctaa 3120 aagattttac cattattttt cctcctttta atagatcatc atgaagaggt cttgtatctc 3180 ttcattcaaa attatttgct catctatgtt aaggaaagtt tcacgatatt tttgtagtaa 3240 ttcactggca gaaatattgc tatacccttc cgatttttgg ttctgattgc ttttactttc 3300 tgcattagct ttttggttgc ttgtagagtt gctatccgtc atactttcat cgatgtttct 3360 gtttgcttgc gttagatagt tgtcgatagc ttttttatag tcgtccccca cttctgtatt 3420 tggttgttca ctatttaagt tcatcgtatc atcataagtg ttgcttgcac ctttggaaac 3480 actatccgat tgactactac cctgtgtaac attgtcaagt gcattttgat aactcatgtt 3540 actaagtggc tcgatcttta ttttttcact ttgatacaat tgattaaaat aaggcatttt 3600 tctatttaaa acttccctaa gcataaattt aaattgcttt ggcatgatta cgcatatttc 3660 actatccaaa tagaaggata ataatttatt atttaacact tctctatgtg cttcatcaaa 3720 aattggataa ttaatagttt cgaaaaattt agcgacaacc gattttttta aagaaccgtc 3780 aacttcaaat atatcttctt ccacttcttc aagaagttgt ttaattgtag gtgcataact 3840 tccaaagtta ctcattttta tcacctacat tcacgatacc caaaagtcct aacattaaaa 3900 acaggttact aattagttta tcccattctc tgttgatgat gtcaacgggt ataacgatat 3960 gaaaccaacc tgttatttgg gctacaatag caataatata agaaacagca acaacccaaa 4020 atattttatt gtttttgttc gctttccata ctttcttgaa ccatgctttc atcttcttcc 4080 ctccctttta tttttacggt aacattagta ccgtaaagtt cgttgaaact atctaatgct 4140 tttcttcttt gatccaacca aacttctcta ttattgaaag tatggttgtc attgctttct 4200 acttccgaag taatcaacct ttctttttta tcggtgtttg cattttctac acctagaaaa 4260 gtgagggctt cattttgaac gtcatgctta taagcggtta gcttatctat tctaaactca 4320 ccttgcaagt ctaatacatc aaccatatca gcaattttga caccttttct tacaaatata 4380 agcggttcat tatgatctac ttgtgcaagt gcattctgca tacttaattt gtttttatta 4440 tccgtttgaa taattctggg acgtttttcg ttgtataaaa gcgtgtcaat agttctttct 4500 atctctgcta atctttctgc gtacatgtca agaatgtaaa aagggcttgt tcttgtatag 4560 tcgttaaaca tgactacaca tgcgttattt tcatcgtata tttttttaac agcttcggga 4620 acattactgt tatatacctg tcttacaaat cccattggat tataactttt atttggtgca 4680 tatgctctta ttgatttagg gttattatat aagtcaaatt gttcaattac aaatggtaag 4740 cagattatac cgaatttttt atcttttaca aaagatattt gaccgtcaaa cataagtcta 4800 ttttctaaat aaaaatcact tatatttaaa tcttcaagac cttcatattc aaacatgcta 4860 taaaatactg tttgtaattg tcttaaatgc cttaaataag cacggtcatt tttatcagag 4920 ttaggaacaa aaggttttgt attcctaggc attcgttcca gtggcattct tttattatat 4980 tcttgttgta aagccttcat tcctttacct gttcttttag ccatgttata cctcctcatt 5040 atttacgtca taattaccaa catcatcagt atgccaaaat gtaacacctt gcgcatatac 5100 ttgttttatt ttttgtaggt agttcattgg aatattacca gttatatttg gttctgcaag 5160 tttgatataa ttaaatttct tcctagtttt atgaacaacg gcaccaaagc gatttacttt 5220 ataaccaaat ttgaaccaat aacgttctag taaataacgg tattccgaag taatcatttt 5280 ttgctttaca gttacaccat atacaccgtt ttgaatatta aacgtcgatc cacctctttg 5340 tgtaaccatg ttattagcag attgtttggc ttgtgattgt tgtgccataa aattaccagc 5400 atataaacca gtatctacca ctgcacctac tgcgttacca gtggctaatt taccgatagc 5460 attaacacct tgtgtaattc ctcccataat catgctattt ttattgaccg aaagaaattg 5520 cgcatacgtg tcagcaactg acggcaataa agggaagtct gttatagaaa gcgcattatc 5580 tgtatccgta tttcctaagt aattcattgg aatgtaggtg acacgtggag aagggtcgat 5640 acttcctctt acttcaattt gaagtgtttt atcttgaaga tattcgggtc gtaacaccat 5700 tgtatcacct gttaaggttg ttacttcaat aaagtaataa gggtacatta ataatttact 5760 ttcgtcaact tttggaagat ttttataagg attgatattt atagtgctag attttgtacc 5820 gtcctcatcg atataactaa tcagcttata gatatttgta tttggtagtt tgtattcctc 5880 catatattta tcttttggaa cacattccaa aggtaagtat gaaagggaca ctatattttc 5940 taataaacta ggtctttctt taaattgatt aaataaatct gctattgcat ttacataggc 6000 aaccatttta cacctcctta caaacctagt aatttggttg ggtctttgta tggcccgaat 6060 acaccagttc cgtcaccata acagaaatgt aagtgaacgc cctggctgtc accagtgttt 6120 cccatttccc caattttttg ctgtcttttc actttatcac caacccgaac atttatatta 6180 cttaaatgtc cgtatcctgt gtgtaaattt aaatcttcat tataaataca aacatagttt 6240 ccaaagctgg cacctggtgt acttgattgg tgatagcttg cataagttac tgttccagag 6300 gtggcactat aaatattgtc accagcaact cctggacttt ctgcgccaaa atcaatacca 6360 ttgtgaacac cgttaggttt gaaaggttgt gttaccctaa cttttttgac tggtttagcg 6420 aatacattac caacatcgtc aacacgtata aattgctgaa caagaggaac atagaacata 6480 tttccgtaag cataacgcca gttataaccc atttttagag caatagggtt attataacta 6540 accttcttac cattagcatg ttctttcgaa aaagacattg cattatcgaa tgtataatca 6600 ccgctataac tgatatatcc agcaccaaag ttataggctt gaacagcttt ccaatcactc 6660 aaatttttat cctttgcaga ttttaaattt gaagctaata attgaactcc ccactttata 6720 gaggtgtctg ggtctggcgc tgatccaggt ggaagccctt gactttctgc cgattgcatt 6780 gggtcatttc cagaacctcc gctttctact tgcataatag cttgaactaa accaacatag 6840 tttggtattc caaattgatt acaatatttt tgaatagtag aaagatagtt tttaacggct 6900 tgattaacgc cagttgcttc accagttgca tcatttcctc cgccgtcgtt tggttcgtca 6960 tctccaccat tagaaccgtt atttcttttt gtgctgtcta atatccaata ttccaaacca 7020 ccagctatac cttgtactac tgtcggttgt ggtggtggaa gatgttccgg aacgtcgcta 7080 cctgttacaa cttttttaag ggcagctttg cttgtaagca atataaaagg actgtacttg 7140 ttattaaaag tttggctgtg aactgtttca tattcttctc ccatttccaa attttctggt 7200 tgtgtattaa cgactggtgt gccgtccttt tcatattgct gttcatgttg tctttctatc 7260 aaactctcat tcacattaaa atcaaataga aatgtttgca tgtaatcgag ttccaaatca 7320 cattcggtta aattatcacc aacaaaatga acatctgtga tgaaaaagaa aagtcttgac 7380 gtgtaaccgt caactacatt atttacaacc gcataattta cttttaaatt gaagtccatg 7440 gcaccgttta tacgcaactt gttatctttg cgaatatact gcaaatttac ttcttctttc 7500 attttaacct cctttctatt aaaaaaggaa attctttcag attcattttt aaatagccga 7560 acgtgagccg ggtcattaga ccacggcacg ttggctataa taacactatt ttttctcgtc 7620 gtgtgcattt tcagcacctt cttcatcaaa gacaccatct aatttacgct cttcagcaat 7680 gttttcactt gcttgttttt gttgcaagtc ttccattgta aacgcttgtt gaccttcttc 7740 ggctttatag tcaatactaa tggcattgaa gaacggtgac atagaaaata ggcggtcatg 7800 atcacggaaa atattcgttt tacgattgat aggattgtaa aatgtagatg tgtttgtata 7860 aacatcacgt attaaaaagg cacgtttatc taccaaccta gcaatagttt gcgtgttttt 7920 cgatccaaaa tcatcaagat taacaatttt aatttgagga aaattaacat cttcacgacc 7980 aaaagcccac gctagaactc tagttgataa aattggctgt agacggtaat caataaataa 8040 cactaaattg cgtgggtctg tagatgtaag cacttttgct ttattgaata atttgctagg 8100 ataagtcaat gcttctgtta gctgtttaat catttcaacc agttcgatga cagtatcttt 8160 attatttttg tcaaaatcgc tttgcatatt cacttgtaaa taaccgttat aggaaccaat 8220 aagttctttt gtgataatat aatcatcaaa ttcactggca acaaatagtt ggcggttaat 8280 cataccgata agtgtattta atccaccttc atcaaaaaag gctttacgca tttgttgata 8340 ttctaatgtc aaaggatatt gatattcaaa gtttttgcgg tgaaaaacaa cttccacagt 8400 tgcggaataa tcttttaaaa agtctgtttc attagcgtca cgattaaaag tattaccttt 8460 gatttcattt acataaacat cttcaatatc attaaagtaa ggcatggaag caccttttag 8520 aaaagccaat ttgttgttaa aatcaaaacc atttactcta atttcaccaa ccaaattgac 8580 aagcccttta aatactacgt tacgctcttg ttcatattca cttgatagta aagcttcacc 8640 aatatttttc aagttatcac gtgaagctac atcaattcga tccgtgtacc acgttggtgc 8700 tgtttctcta attcggttta aaatgtcaac attacttaga acatttggca taattaatta 8760 tctccttttt ctaagcctaa cattgcagat aactgctcgt caaactgttt attttcttct 8820 tctttttgct tgttagccaa ttcatcaatt tgagaggttg aagacttatc ctctgtatta 8880 ctcattgact taatgaataa gctatttacc accttttgct gttcttgata ctccaaatct 8940 ttttgcttgt aactttcatc aattttagca cgttcatttt caaaagcact attcgtcatc 9000 agcaactctt gcgctttttg atgaaacttt tgaggatctt cgatgaagtt agataactct 9060 aaaacaaaat ttttcagttc cgattgtttc acgtgaaaca ctcctttcat taagttacct 9120 ttattatatc actatataat ggaagtaact aggataagta ggtataaagt accatttttt 9180 ataaaacgct tgaaattgtt ctgcattcat ggtattataa aagagtacca aagaggtata 9240 aaaatttttt aggaggtttt atttatgaaa agtattacaa gaacaatcaa atcatcgaaa 9300 gtcaattttg aactaattga cgtggtagaa ggtgaagttg tacgcactac gcacagcgta 9360 acattagaag gttggtatga cacaaaagag gcagagcaag caattgcaaa aaaattgcgt 9420 agtggtgaaa agaatttttt ctctcaaaaa attgttagtg ttttagatat tgattgctct 9480 gctaaaattt acagtgttcc acttgataaa tttatggaaa ttgcaactgt agaggaaggt 9540 catacaaatg aagctgaatg atgaaggttt gcgcctcatt aaatcttttg aaggtttgcg 9600 attgtctgct tattatgatg cagttggtgt actaacaatc ggctacggtc atacaggtag 9660 cgacgtaaca cctggaaaaa gaattagtca acaacaagcg gatatattat tgcatagtga 9720 tgttaaaaga tttgaagttg gggtcaatgc actttctaat gaattgaaat tgaaattgaa 9780 ccaaaatgag tataatgctt tagtttcatt ttcatataat ctaggtctag ggcatacaag 9840 aaccgtaatg accgcataca aaaacaaagg taaagcagag tgcgctagac aaatgttact 9900 ttatgtaaaa gctggcggaa aagttttaaa cggtttagtt agtagaagaa agcaagaggt 9960 tgctcttttc aataaaccaa caaagccagt taagcccgtt gtaaataata aaacgaagca 10020 aatgaaagta actgctacac ttctaaatat tagggaaaaa cctagtatga caggtaaaat 10080 tttaggaact ttgaaaaaga accaaacggt gcaagtgaaa gaaattaaaa acggttgggc 10140 ttatctaaaa tcaaacgata aaactgtata tgtcggtgca aaatatctaa aataatggag 10200 gaatataatc atggaaatta ttaaaagtac aattaaagaa gatacaagag aaggaaaaat 10260 ggctttactt aacgttatca gcggaggtgg aggttctctc aaagaccttg aaaatggtgc 10320 aacatttacc gttacagata ttgttatcac gaagcagtta gtagatcaat acggtaaaga 10380 ggaagaaagc gaagtaacca attttatcac cgaagacgga gaaaatctgg gtagtgtaag 10440 ccccactgta aaagaatttg ctacttcgtt ggctgacgtt ttcgatcaat tagaaagaaa 10500 agctgtactt caagtaatta aaaaacagtc aaacaacaag caagaatata tacttttgca 10560 gattgttggt taaggaggtg aagggcggcg aaagtcgccc tttattttat ggaagataat 10620 cagtatttca caaagagagg aagagcaaaa gacttatcta attcgcctta tatttgtgct 10680 gtttccaatg gtgcaattta ttattttagc acttttagaa acctagaaaa atttatggag 10740 cagatgtacc aaaataggaa agttaaaacc gataagatta taaagatgaa taaaaacttc 10800 cctgtgatca taactacctc catgcaaata tctttcgatg tggatttgta ttccaaaata 10860 caaaaaatat atggttatta cattgagtta gaaggggagg tatacacatg tctggacaac 10920 ctaaatttac acctaatcga aaagatgtag aaagaattat taatttaaat ataaaagcga 10980 aagcaaaggc aaatcgtatt ttaaaaaatt atgatattga tgtatcaagt gatgttacta 11040 ttaagaatgg aatcacaaga aaaaaggata taaataaatc aaaaaatatg ttgaagaaaa 11100 atttttcaag tcgtaaagaa ttcaatgaat atattagtaa tctggatagt tttttgaata 11160 ggaataacaa acgctttcag tataagaaaa ctgcaagcgg aatagttgta aacagacaag 11220 actacaatcg gacacaaaga gagatcaatc gaattaatcg agagagagca aaactaaaaa 11280 ggcaagcgga aagggagaaa gtcacaagag caggtgagga gaaagattat accctaggcg 11340 aagaaagaaa gttaataatg ggagatacga atgaactatc tttaaaggaa gttaaaaatc 11400 catacgatag agcgaacaca atggcgaggg ctaagcagat gttaagagat ttgttaaatt 11460 atcaaaccgt tgaaagtatg gggaaacgat acaaagaaaa ttacattcaa gctataaaaa 11520 acacatttgg gaacgatttg aatgacgttg taagaaagtt aaacaaaatg agtgatagag 11580 attttttatt aatgtaccaa cgtaatgaga taacggatat aggttttatt tatagtcgtt 11640 ttgagtacga agggcatatg caacgaataa gagattttta caatgaaaaa atgtaaagat 11700 ttaagttata cttattcatg tgattttgaa acaactgttc caaaggaaga agattatttt 11760 acaaaaggaa ctagagtttg gtcgtggggc gcaatgaacc ttcaaacgga ggaatttgaa 11820 tataataatt cgattgaaag cttctttgaa cgattttaca attcaaaaaa gaacccaact 11880 ttatattttc acaaccttaa atttgacggt tcatttatca tttatgacct actttttaga 11940 cagggtttta catatgatga tactggaaaa agttcgaaaa gtttttcaat tttaatgaac 12000 gacatgaata cattttatag catcgaaata gtattttgga ggaaaaacaa aaaagtaaag 12060 aagataacta ttttaaactc tctcaataaa attaatagta aagtgaaaga cattgccaaa 12120 gcttatgatt tagaaatcat gaaaggtgaa attgactata agaaagaaag agaagagggt 12180 tatcaaccaa ctagtgatga agttgcctat ttaaagaatg actgttttat agtagggtat 12240 gccttaaaag aacaattcaa acaagggtta gtaaagatga caactggtag cgacgcctta 12300 agcgtataca aagaaatggt gggagagcaa ttttttaata ataattttcc taaattgtcc 12360 tatcaaactt ttaaagatat acacaaagca tatagaggcg gttatactta tttaaagccg 12420 gaacatgtta gtaagattat acatggaggt attgtattcg atgtaaattc tttgtaccct 12480 agcgttatgg aggctaatta ttttccgtat ggtgtacctg tattctttga aggaaaatat 12540 aaaaataatg ctgaatatcc attatatatt caaaaaattg aatgtgaatt tgaaataaaa 12600 gaaggttact taccaacgat acaaataaaa gatagtcaag atttaaggta taatagcacg 12660 gaatacgtta aacagagtaa aggggttaca acgttgtatc tcactaatat tgatcttgat 12720 ttgtttttag aacactatga cgtttattat attgaatata ttaatggttg gtgctttaaa 12780 gctagaaatg acttatttaa tgattatgtt caaaagtgga aggaggttaa agaaaatagt 12840 gacggtgtta ttcgtgaaat tgcaaagcta ttacttaata gcctttacgg taaatttgct 12900 actaatatgg atattgttag taaaaagcct attaaagaag gtgaaatagt gaaatatata 12960 atagacaaag aagaagtaaa agacggtatt tatatacctg taggcgtatt catcactagt 13020 tacgcaagag ataaaacaat aagaagctgt caagctaact acgatagatt tatttatgca 13080 gatactgaca gcatgcactt gaaaggtgta gaaattccaa ataatattga cattcataaa 13140 agtaggttcg gtgcatggaa gcatgaaagc acttttgaaa aaggtaaatt cttaatgagc 13200 aaaaggtata tggaacaaat caaaggagaa atacatgtta aatgtgctgg aatgccagaa 13260 gaggcaaaag aaaatgttac atttgataat tttgagtttg gaacagtttt taaaggtaag 13320 ctatcgccta aaatgataaa gggcggttta gtattgaaag atgttggata tacactaaat 13380 agaaagaagg taatgtaaat ggttgattat ataataggtt ttataagtgg cgctgtggca 13440 atgatcgcaa taattccatt gttgagaaag gaaattaaag gtgactttga aggtgaggac 13500 attatagaag acatgaatga agctaaggca agaaaaaata acattgacaa agatagaaga 13560 ttatgatatt atataagtat ggtaggacaa atttgttaca ttggtattgc tgtgacttga 13620 agcgacctag tcataggaca agcacaaact cattcaatcg ctgaatgctt gccaaacaaa 13680 attgtaccgc ctgtaaatgg tagaaagccg tcgagtggtt gaaaaaccta gacggctttt 13740 ttatatgcta atagtcccac ttataggaca aaatacccac agtgtccgcc ctaccctacc 13800 gaatggggaa acccgttggg agagtaggtg gcgcatgact ttt 13843 SEQUENCE LISTING <110> Optipharm.CO.,LTD <120> Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same <130> OTP1_89_P <160> 1 <170> PatentIn version 3.2 <210> 1 <211> 13843 < 212> DNA <213> Unknown <220> <223> bacteriophage OPT-LM1 <400> 1 aaaagtcatg cgccacctac tctcccaacg ggtttcccca ttcggtaggg tagggcggac 60 actgtgggta ttttgtccta tagttgggac ttaataccta acagattgca tgacatcgat 120 cattagattt ttgacaacca tatcactgaa ccatacttct ccttcatcga agctttcaat 180 gagtaattta aactgcggtg atttacttat agatttaagt aatattgttc cttgtttatg 240 atctgctgaa ttgataacaa atttcaatgg atattgaggg tcaacatcaa aggaacagtg 300 tagacaacta ttgtctatgt cctcccaaat accaatagtt gtattatcat attcaaccga 360 aaacaggtat ttgctacgct taccacgtga acgcacaaaa ttattattgt ctattaaact 420 agcattttca tatgcaaatt cactaaactt tgttccttca attaaactat aaaaacgtgt 480 tttcttcttc tcttccaaaa atttatcatt actgtaatat tccactaata tttcagggtt 540 atgtttaaag gtgttaaacc tcttttttga ggacggtttt aatttgaaat aattgaagta 600 aggatttgct atactaacgt tattactaat tagcaccatt ttgcaagctc tatatccttc 660 catttctctc attcggttga ctgtttcata taagttcaat aacttattaa cctcatcttt 720 tagataaccg tttgatttcc ctcttgcatc aataataaac tcatcaaaaa taatccattc 780 tacatctgta taattgtttg attttaaatt attttctgtg gaaagattga tataaaaacc 840 gcaaacatca tcatcaatgt aaaattttcc accttttaca tcaaatttta catcttgaaa 900 tctatcttct ttcttcactt tatcgaaaaa catacttata ttatcaaatt ctgaatcata 960 tcttctaaca taaataaatt tatatttttt ctttataaac tgctcgacag cgaaagcagt 1020 ccaaccatat gttttaccta atcccctacc gcctattacc atagataata ggcggttata 1080 tgagatagtt tcataagggg aataataaat ttcattatgc acgtgtttgc actactacaa 1140 gccatttact taattctttt gttgtaaagt ttacttgaca ttgtaatatc tccacattat 1200 cagtgcttct acgggttaaa cggataatcc catgcatgtt tacgggtgga ttgtctggca 1260 tgctagggct tccgtcacca gtagttccat ttaaaacttc aacaaaataa ccagcgctgt 1320 caccaattat aatgcttgta tcaggtctat ctttcatttg aagaaaagcg tcattggtaa 1380 tatagtagtt gattggtctt aaattaccaa acttgtagtt atattgctca gggtgaatta 1440 tttcaccata gtaagaaccg ctttgtttaa acgtccaacg tccaaaccac catttcattg 1500 tatctctgtc aaacctcatt tcacggctca tctctagcaa aggctttaca ctatcatgcc 1560 ttgctagtac ttgtctactt gtccatgtag ggcttaaggg tttaacctct aattcgaaac 1620 tattatctcc tacaggtata ggcataccag ggtaattgat aaccatgcta ttatctaggt 1680 gataaattcc tggttctgtg aagtcaccta aagctttcca attgtcacgt ggtctttttg 1740 cttgaccacc tgcaaccatg taaggaaagt tattactgtc aacacgtgcg ccagatataa 1800 agtgacctaa agaacctctt tgaagcatac cgtaaagaag atgataacgt tttgtaatac 1860 cgccatgtgt aacagcaaat aataaacttc tctttttacg ttttttatca taatataaga 1920 acattccttc gggttcttta aaattatctc taggatagcc tataccgtct gggtaaacta 1980 tatcagggtt taatgaaata ctgctatcca ttgtatcacc tttcattgta gtccaacgat 2040 caatgataag ttgattagat atatcacttg tacccttcat ccaatatact tcataacctg 2100 ttacattatt atctttatca taaagtggta aatgtgtaat accttgcata ggtgttttag 2160 cactttcttc tggtttagta ccgtaatttg ttgtaattct atatttaaat ttatctacac 2220 catttcgaac gtccatgcga tcatagatat aaaatagttg ggttccgtta tcatctgttt 2280 gagttagtct taacagtaat gtatcgctaa aaggtt caaa agtaggtgtg atatattttt 2340 ttaaaaatct ttgtggtgta tagtttgtca aaccctttgc ttcttcaagt gatatagtag 2400 tatttggttt atactcaact tgtaccagct ttcctacacc tgtatgatat aaccatatct 2460 ttaaatcacc atttgtattt ctatctaatc cgattgttgt accatgtccg gcgttaggca 2520 agtgcatgac actaatgaag ttcatggaag gagtaaattc attaatgtaa aaaccttcgg 2580 gtgtttgact atcactctgt gttgtatacc accttcctgt ttcataatcg cattgtatgg 2640 attggtttac agcgtttctt aaacctctaa aactttgaag atataaaggt tcttctcttt 2700 ggaagtcaaa cacattttca atatctaaca aaccatttaa tgcaccttca aaattagagg 2760 taaattcttg aattttagca ttaattttac tttcaaaatc agattgacga atgtctaaac 2820 tatcctcata ctctttcatt aattttttaa gttcgtcaaa taaatctata aatttaccct 2880 ctgcatacca ttcgtttaag atatttctaa catcgttttc cagaccttcg ttttcaagaa 2940 attcaagtaa ttcattccat tttttaacta ggtcactttg tattaaaccc atttcttgca 3000 aatattctac aaaattaatt atcattgttc tatagtcata cacatcagct tctacatcgg 3060 gaagatgaaa attctcaata tatgccgaac ttctaaattt gtgcttgaaa aagtttctaa 3120 aagattttac cattattttt cctcctttta atagatcatc a tgaagaggt cttgtatctc 3180 ttcattcaaa attatttgct catctatgtt aaggaaagtt tcacgatatt tttgtagtaa 3240 ttcactggca gaaatattgc tatacccttc cgatttttgg ttctgattgc ttttactttc 3300 tgcattagct ttttggttgc ttgtagagtt gctatccgtc atactttcat cgatgtttct 3360 gtttgcttgc gttagatagt tgtcgatagc ttttttatag tcgtccccca cttctgtatt 3420 tggttgttca ctatttaagt tcatcgtatc atcataagtg ttgcttgcac ctttggaaac 3480 actatccgat tgactactac cctgtgtaac attgtcaagt gcattttgat aactcatgtt 3540 actaagtggc tcgatcttta ttttttcact ttgatacaat tgattaaaat aaggcatttt 3600 tctatttaaa acttccctaa gcataaattt aaattgcttt ggcatgatta cgcatatttc 3660 actatccaaa tagaaggata ataatttatt atttaacact tctctatgtg cttcatcaaa 3720 aattggataa ttaatagttt cgaaaaattt agcgacaacc gattttttta aagaaccgtc 3780 aacttcaaat atatcttctt ccacttcttc aagaagttgt ttaattgtag gtgcataact 3840 tccaaagtta ctcattttta tcacctacat tcacgatacc caaaagtcct aacattaaaa 3900 acaggttact aattagttta tcccattctc tgttgatgat gtcaacgggt ataacgatat 3960 gaaaccaacc tgttatttgg gctacaatag caataatata agaaaca gca acaacccaaa 4020 atattttatt gtttttgttc gctttccata ctttcttgaa ccatgctttc atcttcttcc 4080 ctccctttta tttttacggt aacattagta ccgtaaagtt cgttgaaact atctaatgct 4140 tttcttcttt gatccaacca aacttctcta ttattgaaag tatggttgtc attgctttct 4200 acttccgaag taatcaacct ttctttttta tcggtgtttg cattttctac acctagaaaa 4260 gtgagggctt cattttgaac gtcatgctta taagcggtta gcttatctat tctaaactca 4320 ccttgcaagt ctaatacatc aaccatatca gcaattttga caccttttct tacaaatata 4380 agcggttcat tatgatctac ttgtgcaagt gcattctgca tacttaattt gtttttatta 4440 tccgtttgaa taattctggg acgtttttcg ttgtataaaa gcgtgtcaat agttctttct 4500 atctctgcta atctttctgc gtacatgtca agaatgtaaa aagggcttgt tcttgtatag 4560 tcgttaaaca tgactacaca tgcgttattt tcatcgtata tttttttaac agcttcggga 4620 acattactgt tatatacctg tcttacaaat cccattggat tataactttt atttggtgca 4680 tatgctctta ttgatttagg gttattatat aagtcaaatt gttcaattac aaatggtaag 4740 cagattatac cgaatttttt atcttttaca aaagatattt gaccgtcaaa cataagtcta 4800 ttttctaaat aaaaatcact tatatttaaa tcttcaagac cttcatattc aa acatgcta 4860 taaaatactg tttgtaattg tcttaaatgc cttaaataag cacggtcatt tttatcagag 4920 ttaggaacaa aaggttttgt attcctaggc attcgttcca gtggcattct tttattatat 4980 tcttgttgta aagccttcat tcctttacct gttcttttag ccatgttata cctcctcatt 5040 atttacgtca taattaccaa catcatcagt atgccaaaat gtaacacctt gcgcatatac 5100 ttgttttatt ttttgtaggt agttcattgg aatattacca gttatatttg gttctgcaag 5160 tttgatataa ttaaatttct tcctagtttt atgaacaacg gcaccaaagc gatttacttt 5220 ataaccaaat ttgaaccaat aacgttctag taaataacgg tattccgaag taatcatttt 5280 ttgctttaca gttacaccat atacaccgtt ttgaatatta aacgtcgatc cacctctttg 5340 tgtaaccatg ttattagcag attgtttggc ttgtgattgt tgtgccataa aattaccagc 5400 atataaacca gtatctacca ctgcacctac tgcgttacca gtggctaatt taccgatagc 5460 attaacacct tgtgtaattc ctcccataat catgctattt ttattgaccg aaagaaattg 5520 cgcatacgtg tcagcaactg acggcaataa agggaagtct gttatagaaa gcgcattatc 5580 tgtatccgta tttcctaagt aattcattgg aatgtaggtg acacgtggag aagggtcgat 5640 acttcctctt acttcaattt gaagtgtttt atcttgaaga tattcgggtc gtaacacc at 5700 tgtatcacct gttaaggttg ttacttcaat aaagtaataa gggtacatta ataatttact 5760 ttcgtcaact tttggaagat ttttataagg attgatattt atagtgctag attttgtacc 5820 gtcctcatcg atataactaa tcagcttata gatatttgta tttggtagtt tgtattcctc 5880 catatattta tcttttggaa cacattccaa aggtaagtat gaaagggaca ctatattttc 5940 taataaacta ggtctttctt taaattgatt aaataaatct gctattgcat ttacataggc 6000 aaccatttta cacctcctta caaacctagt aatttggttg ggtctttgta tggcccgaat 6060 acaccagttc cgtcaccata acagaaatgt aagtgaacgc cctggctgtc accagtgttt 6120 cccatttccc caattttttg ctgtcttttc actttatcac caacccgaac atttatatta 6180 cttaaatgtc cgtatcctgt gtgtaaattt aaatcttcat tataaataca aacatagttt 6240 ccaaagctgg cacctggtgt acttgattgg tgatagcttg cataagttac tgttccagag 6300 gtggcactat aaatattgtc accagcaact cctggacttt ctgcgccaaa atcaatacca 6360 ttgtgaacac cgttaggttt gaaaggttgt gttaccctaa cttttttgac tggtttagcg 6420 aatacattac caacatcgtc aacacgtata aattgctgaa caagaggaac atagaacata 6480 tttccgtaag cataacgcca gttataaccc atttttagag caatagggtt attataacta 654 0 accttcttac cattagcatg ttctttcgaa aaagacattg cattatcgaa tgtataatca 6600 ccgctataac tgatatatcc agcaccaaag ttataggctt gaacagcttt ccaatcactc 6660 aaatttttat cctttgcaga ttttaaattt gaagctaata attgaactcc ccactttata 6720 gaggtgtctg ggtctggcgc tgatccaggt ggaagccctt gactttctgc cgattgcatt 6780 gggtcatttc cagaacctcc gctttctact tgcataatag cttgaactaa accaacatag 6840 tttggtattc caaattgatt acaatatttt tgaatagtag aaagatagtt tttaacggct 6900 tgattaacgc cagttgcttc accagttgca tcatttcctc cgccgtcgtt tggttcgtca 6960 tctccaccat tagaaccgtt atttcttttt gtgctgtcta atatccaata ttccaaacca 7020 ccagctatac cttgtactac tgtcggttgt ggtggtggaa gatgttccgg aacgtcgcta 7080 cctgttacaa cttttttaag ggcagctttg cttgtaagca atataaaagg actgtacttg 7140 ttattaaaag tttggctgtg aactgtttca tattcttctc ccatttccaa attttctggt 7200 tgtgtattaa cgactggtgt gccgtccttt tcatattgct gttcatgttg tctttctatc 7260 aaactctcat tcacattaaa atcaaataga aatgtttgca tgtaatcgag ttccaaatca 7320 cattcggtta aattatcacc aacaaaatga acatctgtga tgaaaaagaa aagtcttgac 7380 gtgt aaccgt caactacatt atttacaacc gcataattta cttttaaatt gaagtccatg 7440 gcaccgttta tacgcaactt gttatctttg cgaatatact gcaaatttac ttcttctttc 7500 attttaacct cctttctatt aaaaaaggaa attctttcag attcattttt aaatagccga 7560 acgtgagccg ggtcattaga ccacggcacg ttggctataa taacactatt ttttctcgtc 7620 gtgtgcattt tcagcacctt cttcatcaaa gacaccatct aatttacgct cttcagcaat 7680 gttttcactt gcttgttttt gttgcaagtc ttccattgta aacgcttgtt gaccttcttc 7740 ggctttatag tcaatactaa tggcattgaa gaacggtgac atagaaaata ggcggtcatg 7800 atcacggaaa atattcgttt tacgattgat aggattgtaa aatgtagatg tgtttgtata 7860 aacatcacgt attaaaaagg cacgtttatc taccaaccta gcaatagttt gcgtgttttt 7920 cgatccaaaa tcatcaagat taacaatttt aatttgagga aaattaacat cttcacgacc 7980 aaaagcccac gctagaactc tagttgataa aattggctgt agacggtaat caataaataa 8040 cactaaattg cgtgggtctg tagatgtaag cacttttgct ttattgaata atttgctagg 8100 ataagtcaat gcttctgtta gctgtttaat catttcaacc agttcgatga cagtatcttt 8160 attatttttg tcaaaatcgc tttgcatatt cacttgtaaa taaccgttat aggaaccaat 8220 aagttctttt gtgataatat aatcatcaaa ttcactggca acaaatagtt ggcggttaat 8280 cataccgata agtgtattta atccaccttc atcaaaaaag gctttacgca tttgttgata 8340 ttctaatgtc aaaggatatt gatattcaaa gtttttgcgg tgaaaaacaa cttccacagt 8400 tgcggaataa tcttttaaaa agtctgtttc attagcgtca cgattaaaag tattaccttt 8460 gatttcattt acataaacat cttcaatatc attaaagtaa ggcatggaag caccttttag 8520 aaaagccaat ttgttgttaa aatcaaaacc atttactcta atttcaccaa ccaaattgac 8580 aagcccttta aatactacgt tacgctcttg ttcatattca cttgatagta aagcttcacc 8640 aatatttttc aagttatcac gtgaagctac atcaattcga tccgtgtacc acgttggtgc 8700 tgtttctcta attcggttta aaatgtcaac attacttaga acatttggca taattaatta 8760 tctccttttt ctaagcctaa cattgcagat aactgctcgt caaactgttt attttcttct 8820 tctttttgct tgttagccaa ttcatcaatt tgagaggttg aagacttatc ctctgtatta 8880 ctcattgact taatgaataa gctatttacc accttttgct gttcttgata ctccaaatct 8940 ttttgcttgt aactttcatc aattttagca cgttcatttt caaaagcact attcgtcatc 9000 agcaactctt gcgctttttg atgaaacttt tgaggatctt cgatgaagtt agataactct 9060 aaaacaaaat ttttc agttc cgattgtttc acgtgaaaca ctcctttcat taagttacct 9120 ttattatatc actatataat ggaagtaact aggataagta ggtataaagt accatttttt 9180 ataaaacgct tgaaattgtt ctgcattcat ggtattataa aagagtacca aagaggtata 9240 aaaatttttt aggaggtttt atttatgaaa agtattacaa gaacaatcaa atcatcgaaa 9300 gtcaattttg aactaattga cgtggtagaa ggtgaagttg tacgcactac gcacagcgta 9360 acattagaag gttggtatga cacaaaagag gcagagcaag caattgcaaa aaaattgcgt 9420 agtggtgaaa agaatttttt ctctcaaaaa attgttagtg ttttagatat tgattgctct 9480 gctaaaattt acagtgttcc acttgataaa tttatggaaa ttgcaactgt agaggaaggt 9540 catacaaatg aagctgaatg atgaaggttt gcgcctcatt aaatcttttg aaggtttgcg 9600 attgtctgct tattatgatg cagttggtgt actaacaatc ggctacggtc atacaggtag 9660 cgacgtaaca cctggaaaaa gaattagtca acaacaagcg gatatattat tgcatagtga 9720 tgttaaaaga tttgaagttg gggtcaatgc actttctaat gaattgaaat tgaaattgaa 9780 ccaaaatgag tataatgctt tagtttcatt ttcatataat ctaggtctag ggcatacaag 9840 aaccgtaatg accgcataca aaaacaaagg taaagcagag tgcgctagac aaatgttact 9900 ttatgtaaaa gctggcggaa aagttttaaa cggtttagtt agtagaagaa agcaagaggt 9960 tgctcttttc aataaaccaa caaagccagt taagcccgtt gtaaataata aaacgaagca 10020 aatgaaagta actgctacac ttctaaatat tagggaaaaa cctagtatga caggtaaaat 10080 tttaggaact ttgaaaaaga accaaacggt gcaagtgaaa gaaattaaaa acggttgggc 10140 ttatctaaaa tcaaacgata aaactgtata tgtcggtgca aaatatctaa aataatggag 10200 gaatataatc atggaaatta ttaaaagtac aattaaagaa gatacaagag aaggaaaaat 10260 ggctttactt aacgttatca gcggaggtgg aggttctctc aaagaccttg aaaatggtgc 10320 aacatttacc gttacagata ttgttatcac gaagcagtta gtagatcaat acggtaaaga 10380 ggaagaaagc gaagtaacca attttatcac cgaagacgga gaaaatctgg gtagtgtaag 10440 ccccactgta aaagaatttg ctacttcgtt ggctgacgtt ttcgatcaat tagaaagaaa 10500 agctgtactt caagtaatta aaaaacagtc aaacaacaag caagaatata tacttttgca 10560 gattgttggt taaggaggtg aagggcggcg aaagtcgccc tttattttat ggaagataat 10620 cagtatttca caaagagagg aagagcaaaa gacttatcta attcgcctta tatttgtgct 10680 gtttccaatg gtgcaattta ttattttagc acttttagaa acctagaaaa atttatggag 10740 cagatgtacc aaaa taggaa agttaaaacc gataagatta taaagatgaa taaaaacttc 10800 cctgtgatca taactacctc catgcaaata tctttcgatg tggatttgta ttccaaaata 10860 caaaaaatat atggttatta cattgagtta gaaggggagg tatacacatg tctggacaac 10920 ctaaatttac acctaatcga aaagatgtag aaagaattat taatttaaat ataaaagcga 10980 aagcaaaggc aaatcgtatt ttaaaaaatt atgatattga tgtatcaagt gatgttacta 11040 ttaagaatgg aatcacaaga aaaaaggata taaataaatc aaaaaatatg ttgaagaaaa 11100 atttttcaag tcgtaaagaa ttcaatgaat atattagtaa tctggatagt tttttgaata 11160 ggaataacaa acgctttcag tataagaaaa ctgcaagcgg aatagttgta aacagacaag 11220 actacaatcg gacacaaaga gagatcaatc gaattaatcg agagagagca aaactaaaaa 11280 ggcaagcgga aagggagaaa gtcacaagag caggtgagga gaaagattat accctaggcg 11340 aagaaagaaa gttaataatg ggagatacga atgaactatc tttaaaggaa gttaaaaatc 11400 catacgatag agcgaacaca atggcgaggg ctaagcagat gttaagagat ttgttaaatt 11460 atcaaaccgt tgaaagtatg gggaaacgat acaaagaaaa ttacattcaa gctataaaaa 11520 acacatttgg gaacgatttg aatgacgttg taagaaagtt aaacaaaatg agtgatagag 11580 atttttt att aatgtaccaa cgtaatgaga taacggatat aggttttatt tatagtcgtt 11640 ttgagtacga agggcatatg caacgaataa gagattttta caatgaaaaa atgtaaagat 11700 ttaagttata cttattcatg tgattttgaa acaactgttc caaaggaaga agattatttt 11760 acaaaaggaa ctagagtttg gtcgtggggc gcaatgaacc ttcaaacgga ggaatttgaa 11820 tataataatt cgattgaaag cttctttgaa cgattttaca attcaaaaaa gaacccaact 11880 ttatattttc acaaccttaa atttgacggt tcatttatca tttatgacct actttttaga 11940 cagggtttta catatgatga tactggaaaa agttcgaaaa gtttttcaat tttaatgaac 12000 gacatgaata cattttatag catcgaaata gtattttgga ggaaaaacaa aaaagtaaag 12060 aagataacta ttttaaactc tctcaataaa attaatagta aagtgaaaga cattgccaaa 12120 gcttatgatt tagaaatcat gaaaggtgaa attgactata agaaagaaag agaagagggt 12180 tatcaaccaa ctagtgatga agttgcctat ttaaagaatg actgttttat agtagggtat 12240 gccttaaaag aacaattcaa acaagggtta gtaaagatga caactggtag cgacgcctta 12300 agcgtataca aagaaatggt gggagagcaa ttttttaata ataattttcc taaattgtcc 12360 tatcaaactt ttaaagatat acacaaagca tatagaggcg gttatactta tttaaagccg 12420 gaacatgtta gtaagattat acatggaggt attgtattcg atgtaaattc tttgtaccct 12480 agcgttatgg aggctaatta ttttccgtat ggtgtacctg tattctttga aggaaaatat 12540 aaaaataatg ctgaatatcc attatatatt caaaaaattg aatgtgaatt tgaaataaaa 12600 gaaggttact taccaacgat acaaataaaa gatagtcaag atttaaggta taatagcacg 12660 gaatacgtta aacagagtaa aggggttaca acgttgtatc tcactaatat tgatcttgat 12720 ttgtttttag aacactatga cgtttattat attgaatata ttaatggttg gtgctttaaa 12780 gctagaaatg acttatttaa tgattatgtt caaaagtgga aggaggttaa agaaaatagt 12840 gacggtgtta ttcgtgaaat tgcaaagcta ttacttaata gcctttacgg taaatttgct 12900 actaatatgg atattgttag taaaaagcct attaaagaag gtgaaatagt gaaatatata 12960 atagacaaag aagaagtaaa agacggtatt tatatacctg taggcgtatt catcactagt 13020 tacgcaagag ataaaacaat aagaagctgt caagctaact acgatagatt tatttatgca 13080 gatactgaca gcatgcactt gaaaggtgta gaaattccaa ataatattga cattcataaa 13140 agtaggttcg gtgcatggaa gcatgaaagc acttttgaaa aaggtaaatt cttaatgagc 13200 aaaaggtata tggaacaaat caaaggagaa atacatgtta aatgtgctgg aatgccag aa 13260 gaggcaaaag aaaatgttac atttgataat tttgagtttg gaacagtttt taaaggtaag 13320 ctatcgccta aaatgataaa gggcggttta gtattgaaag atgttggata tacactaaat 13380 agaaagaagg taatgtaaat ggttgattat ataataggtt ttataagtgg cgctgtggca 13440 atgatcgcaa taattccatt gttgagaaag gaaattaaag gtgactttga aggtgaggac 13500 attatagaag acatgaatga agctaaggca agaaaaaata acattgacaa agatagaaga 13560 ttatgatatt atataagtat ggtaggacaa atttgttaca ttggtattgc tgtgacttga 13620 agcgacctag tcataggaca agcacaaact cattcaatcg ctgaatgctt gccaaacaaa 13680 attgtaccgc ctgtaaatgg tagaaagccg tcgagtggtt gaaaaaccta gacggctttt 13740 ttatatgcta atagtcccac ttataggaca aaatacccac agtgtccgcc ctaccctacc 13800gaatggggaa acccgttggg agagtaggtg gcgcatgact ttt 13843

Claims (9)

리스테리아 모노사이토제네스(Listeria monocytogenes)에 특이적인 사멸능을 갖는, 서열번호 1로 표시되는 염기서열로 이루어진 박테리오파지 OPT-LM1(수탁번호 KFCC11839P).Listeria monocytogenes ( Listeria monocytogenes ) Bacteriophage OPT-LM1 (Accession No. KFCC11839P) consisting of the nucleotide sequence represented by SEQ ID NO: 1 having a specific killing ability. 삭제delete 제 1항의 박테리오파지 OPT-LM1을 포함하는, 항생용 조성물. A composition for antibiotics comprising the bacteriophage OPT-LM1 of claim 1. 제 1항의 박테리오파지 OPT-LM1을 포함하는, 사료 첨가용 조성물. A composition for feed addition comprising the bacteriophage OPT-LM1 of claim 1. 제 4항의 사료 첨가용 조성물을 포함하는, 사료. A feed comprising the composition for feed addition of claim 4. 제 1항의 박테리오파지 OPT-LM1을 포함하는, 소독제. A disinfectant comprising the bacteriophage OPT-LM1 of claim 1. 제 1항의 박테리오파지 OPT-LM1을 포함하는, 세척제. A cleaning agent comprising the bacteriophage OPT-LM1 of claim 1. 삭제delete 삭제delete
KR1020200088369A 2020-07-16 2020-07-16 Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same KR102359655B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200088369A KR102359655B1 (en) 2020-07-16 2020-07-16 Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200088369A KR102359655B1 (en) 2020-07-16 2020-07-16 Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same

Publications (2)

Publication Number Publication Date
KR20220009766A KR20220009766A (en) 2022-01-25
KR102359655B1 true KR102359655B1 (en) 2022-02-08

Family

ID=80049053

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200088369A KR102359655B1 (en) 2020-07-16 2020-07-16 Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same

Country Status (1)

Country Link
KR (1) KR102359655B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194000A1 (en) 2007-02-12 2008-08-14 Intralytix, Inc. Novel listeria monocytogenes bacteriophage and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194000A1 (en) 2007-02-12 2008-08-14 Intralytix, Inc. Novel listeria monocytogenes bacteriophage and uses thereof
WO2008100273A1 (en) 2007-02-12 2008-08-21 Intralytix, Inc. Novel listeria monocytogenes bacteriophage and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Food Control. 2017, Volume 75, May 2017, Pages 108-115.
Korean J. Food Sci. Anim. Resour. 2017, Volume 37, No 2, Pages 320-328.

Also Published As

Publication number Publication date
KR20220009766A (en) 2022-01-25

Similar Documents

Publication Publication Date Title
JP5103531B2 (en) Novel bacteriophage and antibacterial composition containing the same
JP6110515B2 (en) Novel bacteriophage and antibacterial composition containing the same
JP6130935B2 (en) Novel bacteriophage and antibacterial composition containing the same
JP5079885B2 (en) Novel bacteriophage and antibacterial composition containing the same
JP5970138B2 (en) Novel bacteriophage and antibacterial composition containing the same
JP5666016B2 (en) Novel bacteriophage and antimicrobial composition containing the same
JP2011514802A (en) Novel bacteriophage and antibacterial composition containing the same
JP6059827B2 (en) Novel bacteriophage and antibacterial composition containing the same
JP6069533B2 (en) Novel bacteriophage and antibacterial composition containing the same
JP6324536B2 (en) New bacteriophage and composition containing the same
KR20150118837A (en) Novel bacteriophage and composition comprising the same
KR102193499B1 (en) Novel Bacillus cereus bacteria specific bacteriophage BC13 and antibacterial composition comprising the same
KR102016920B1 (en) Novel Clostridium perfringens specific bacteriophage CP5 and antibacterial composition comprising the same
KR20180042748A (en) Novel Staphylococcus specific bacteriophage SA7 and antibacterial composition comprising the same
KR102203679B1 (en) Novel Enterococcus faecium specific bacteriophage EF44 and antibacterial composition comprising the same
KR101830900B1 (en) Novel avian pathogenic Escherichia coli specific bacteriophage EC13 and antibacterial composition comprising the same
KR102359655B1 (en) Novel Listeria specific bacteriophage OPT-LM1 and antibacterial composition comprising the same
KR102037383B1 (en) Novel Vibrio specific bacteriophage VP2 and antibacterial composition comprising the same
KR101871342B1 (en) Novel Salmonella specific bacteriophage ST1 and antibacterial composition comprising the same
KR102193477B1 (en) Novel Salmonella specific bacteriophage ST20 and antibacterial composition comprising the same
KR102037398B1 (en) Novel Salmonella specific bacteriophage SG102 and antibacterial composition comprising the same
KR20190069947A (en) Novel Vibrio specific bacteriophage VP4 and antibacterial composition comprising the same
KR102016921B1 (en) Novel Salmonella specific bacteriophage SE131 and antibacterial composition comprising the same
KR102003795B1 (en) Novel shiga toxin producing Escherichia coli specific bacteriophage ECOH1 and antibacterial composition comprising the same
KR101842668B1 (en) Novel Salmonella specific becteriophage SG2 and antibacterial composition comprising the same

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant